Ching-Hong Pui

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7325851/publications.pdf

Version: 2024-02-01

869	75,875	334 137	783 248
papers	citations	h-index	g-index

909	909	909	41483
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell, 2002, 1, 133-143.	7.7	1,756
2	Treatment of Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2006, 354, 166-178.	13.9	1,740
3	Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature, 2007, 446, 758-764.	13.7	1,602
4	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature, 2012, 481, 157-163.	13.7	1,430
5	Acute lymphoblastic leukaemia. Lancet, The, 2008, 371, 1030-1043.	6.3	1,308
6	Deletion ofIKZF1and Prognosis in Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2009, 360, 470-480.	13.9	1,260
7	Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2014, 371, 1005-1015.	13.9	1,161
8	Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2004, 350, 1535-1548.	13.9	1,081
9	Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation. New England Journal of Medicine, 2009, 360, 2730-2741.	13.9	1,059
10	Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell, 2002, 1, 75-87.	7.7	1,024
11	BCRâ€“ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature, 2008, 453, 110-114.	13.7	955
12	Germline Mutations in Predisposition Genes in Pediatric Cancer. New England Journal of Medicine, 2015, 373, 2336-2346.	13.9	949
13	Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncology, The, 2009, 10, 147-156.	5.1	850
14	The Tumor Lysis Syndrome. New England Journal of Medicine, 2011, 364, 1844-1854.	13.9	816
15	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 2022, 140, 1200-1228.	0.6	814
16	Acute Lymphoblastic Leukemia. New England Journal of Medicine, 1998, 339, 605-615.	13.9	809
17	Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. Journal of Clinical Oncology, 2015, 33, 2938-2948.	0.8	747
18	Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update. Journal of Clinical Oncology, 2011, 29, 551-565.	0.8	712

#	Article	IF	Citations
19	Acute Myeloid Leukemia in Children Treated with Epipodophyllotoxins for Acute Lymphoblastic Leukemia. New England Journal of Medicine, 1991, 325, 1682-1687.	13.9	697
20	Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review. Journal of Clinical Oncology, 2008, 26, 2767-2778.	0.8	637
21	Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia. Cancer Cell, 2012, 22, 153-166.	7.7	621
22	The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nature Genetics, 2013, 45, 242-252.	9.4	588
23	Gene-Expression Patterns in Drug-Resistant Acute Lymphoblastic Leukemia Cells and Response to Treatment. New England Journal of Medicine, 2004, 351, 533-542.	13.9	565
24	NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 955-959.	0.8	563
25	Rearrangement of CRLF2 in B-progenitorâ€“ and Down syndromeâ€“associated acute lymphoblastic leukemia. Nature Genetics, 2009, 41, 1243-1246.	9.4	559
26	Preventing and Managing Toxicities of High-Dose Methotrexate. Oncologist, 2016, 21, 1471-1482.	1.9	550
27	CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature, 2011, 471, 235-239.	13.7	542
28	Outcome of Treatment in Children with Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2000, 342, 998-1006.	13.9	539
29	Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncology, The, 2010, 11, 543-552.	5.1	514
30	Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nature Genetics, 2009, 41, 1001-1005.	9.4	459
31	Lâ€asparaginase treatment in acute lymphoblastic leukemia. Cancer, 2011, 117, 238-249.	2.0	453
32	Secondary Acute Myeloid Leukemia in Children Treated for Acute Lymphoid Leukemia. New England Journal of Medicine, 1989, 321, 136-142.	13.9	444
33	Childhood Leukemias. New England Journal of Medicine, 1995, 332, 1618-1630.	13.9	440
34	Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?. Blood, 2012, 120, 1165-1174.	0.6	439
35	Conventional Compared with Individualized Chemotherapy for Childhood Acute Lymphoblastic Leukemia. New England Journal of Medicine, 1998, 338, 499-505.	13.9	438
36	Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on <scp>TPMT</scp> and <scp>NUDT</scp>15 Genotypes: 2018 Update. Clinical Pharmacology and Therapeutics, 2019, 105, 1095-1105.	2.3	428

#	Article	IF	Citations
37	Extended Follow-up of Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2003, 349, 640-649.	13.9	415
38	Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood, 2004, 104, 2690-2696.	0.6	412
39	Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood, 2000, 96, 2691-2696.	0.6	406
40	The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nature Genetics, 2015, 47, 330-337.	9.4	405
41	Gene expression profiling of pediatric acute myelogenous leukemia. Blood, 2004, 104, 3679-3687.	0.6	404
42	Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet, The, 1998, 351, 550-554.	6.3	402
43	High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet, The, 1999, 354, 34-39.	6.3	390
44	NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nature Genetics, 2016, 48, 367-373.	9.4	389
45	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nature Genetics, 2019, 51, 296-307.	9.4	384
46	Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic Leukemia. New England Journal of Medicine, 1986, 314, 471-477.	13.9	369
47	Inherited NUDT15 Variant Is a Genetic Determinant of Mercaptopurine Intolerance in Children With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2015, 33, 1235-1242.	0.8	369
48	Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood, 2012, 120, 5173-5180.	0.6	368
49	Biological and therapeutic aspects of infant leukemia. Blood, 2000, 96, 24-33.	0.6	358
50	Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet, The, 2009, 374, 159-169.	6.3	351
51	Prognostic Importance of 6-Mercaptopurine Dose Intensity in Acute Lymphoblastic Leukemia. Blood, 1999, 93, 2817-2823.	0.6	348
52	Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet, The, 2002, 359, 1909-1915.	6.3	338
53	Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncology, The, 2013, 14, e205-e217.	5.1	338
54	Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncology, The, 2008, 9, 257-268.	5.1	330

#	Article	IF	Citations
55	Recombinant Urate Oxidase for the Prophylaxis or Treatment of Hyperuricemia in Patients With Leukemia or Lymphoma. Journal of Clinical Oncology, 2001, 19, 697-704.	0.8	318
56	The Pediatric Cancer Genome Project. Nature Genetics, 2012, 44, 619-622.	9.4	315
57	Toward the Cure of All Children With Cancer Through Collaborative Efforts: Pediatric Oncology As a Global Challenge. Journal of Clinical Oncology, 2015, 33, 3065-3073.	0.8	312
58	Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical Effects. Journal of Clinical Oncology, 2009, 27, 5972-5978.	0.8	305
59	Cancer Survivorshipâ€"Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations. Journal of the National Cancer Institute, 2006, 98, 15-25.	3.0	295
60	Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. Journal of Clinical Investigation, 2007, 117, 1049-1057.	3.9	293
61	Higher Frequency of Glutathione S-Transferase Deletions in Black Children With Acute Lymphoblastic Leukemia. Blood, 1997, 89, 1701-1707.	0.6	283
62	Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncology, The, 2010, 11, 1096-1106.	5.1	282
63	Methotrexate-Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2014, 32, 949-959.	0.8	275
64	New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood, 2011, 117, 6267-6276.	0.6	273
65	Neurocognitive Outcomes Decades After Treatment for Childhood Acute Lymphoblastic Leukemia: A Report From the St Jude Lifetime Cohort Study. Journal of Clinical Oncology, 2013, 31, 4407-4415.	0.8	266
66	A 50-Year Journey to Cure Childhood Acute Lymphoblastic Leukemia. Seminars in Hematology, 2013, 50, 185-196.	1.8	264
67	Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nature Genetics, 2013, 45, 1494-1498.	9.4	264
68	Cumulative Incidence of Secondary Neoplasms as a First Event After Childhood Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2007, 297, 1207.	3.8	261
69	Establishment of a Pediatric Oncology Program and Outcomes of Childhood Acute Lymphoblastic Leukemia in a Resource-Poor Area. JAMA - Journal of the American Medical Association, 2004, 291, 2471.	3.8	256
70	Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2012, 366, 1371-1381.	13.9	252
71	Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. Lancet Oncology, The, 2014, 15, 1215-1223.	5.1	252
72	Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood, 2007, 110, 1112-1115.	0.6	250

#	Article	IF	Citations
73	Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia, 2010, 24, 371-382.	3.3	248
74	Thiopurine methyltransferase activity in American white subjects and black subjects. Clinical Pharmacology and Therapeutics, 1994, 55, 15-20.	2.3	242
75	Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia. EBioMedicine, 2016, 8, 173-183.	2.7	241
76	Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood, 2002, 100, 52-58.	0.6	240
77	Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nature Genetics, 2003, 34, 85-90.	9.4	239
78	Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nature Genetics, 2011, 43, 237-241.	9.4	239
79	Childhood acute lymphoblastic leukaemia â€“ current status and future perspectives. Lancet Oncology, The, 2001, 2, 597-607.	5.1	237
80	The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature, 2018, 562, 373-379.	13.7	236
81	Association of an Inherited Genetic Variant With Vincristine-Related Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2015, 313, 815.	3.8	234
82	Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Research, 2012, 22, 1-8.	2.4	232
83	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nature Genetics, 2016, 48, 1481-1489.	9.4	231
84	Childhood cancer epidemiology in lowâ€income countries. Cancer, 2008, 112, 461-472.	2.0	228
85	Adult acute lymphoblastic leukemia. Cancer, 2010, 116, 1165-1176.	2.0	225
86	Outcomes of Children With BCR-ABL1â€“Like Acute Lymphoblastic Leukemia Treated With Risk-Directed Therapy Based on the Levels of Minimal Residual Disease. Journal of Clinical Oncology, 2014, 32, 3012-3020.	0.8	223
87	PG4KDS: A model for the clinical implementation of preâ€emptive pharmacogenetics. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2014, 166, 45-55.	0.7	221
88	Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood, 2011, 117, 2340-2347.	0.6	219
89	Anterior Hypopituitarism in Adult Survivors of Childhood Cancers Treated With Cranial Radiotherapy: A Report From the St Jude Lifetime Cohort Study. Journal of Clinical Oncology, 2015, 33, 492-500.	0.8	216
90	The genomic landscape of core-binding factor acute myeloid leukemias. Nature Genetics, 2016, 48, 1551-1556.	9.4	215

#	Article	IF	Citations
91	Late Effects of Treatment in Survivors of Childhood Acute Myeloid Leukemia. Journal of Clinical Oncology, 2000, 18, 3273-3279.	0.8	213
92	An Inv(16)(p13.3q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein Defines an Aggressive Subtype of Pediatric Acute Megakaryoblastic Leukemia. Cancer Cell, 2012, 22, 683-697.	7.7	213
93	Novel Susceptibility Variants at 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations. Journal of the National Cancer Institute, 2013, 105, 733-742.	3.0	208
94	Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood, 2005, 105, 4752-4758.	0.6	205
95	Clinical Outcome of Children With Newly Diagnosed Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia Treated Between 1995 and 2005. Journal of Clinical Oncology, 2010, 28, 4755-4761.	0.8	203
96	New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nature Reviews Drug Discovery, 2007, 6, 149-165.	21.5	200
97	Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2009, 301, 393.	3.8	193
98	Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood, 2001, 97, 3727-3732.	0.6	192
99	Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11711-E11720.	3.3	192
100	Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood, 2007, 109, 4151-4157.	0.6	190
101	Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood, 2014, 123, 70-77.	0.6	189
102	Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2012, 30, 3625-3632.	0.8	188
103	Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy. Journal of the National Cancer Institute, 2012, 104, 357-370.	3.0	187
104	Low Leukocyte Counts with Blast Cells in Cerebrospinal Fluid of Children with Newly Diagnosed Acute Lymphoblastic Leukemia. New England Journal of Medicine, 1993, 329, 314-319.	13.9	186
105	Early Intensification of Intrathecal Chemotherapy Virtually Eliminates Central Nervous System Relapse in Children With Acute Lymphoblastic Leukemia. Blood, 1998, 92, 411-415.	0.6	183
106	Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet, The, 2000, 356, 285-290.	6.3	181
107	Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood, 2000, 96, 3381-3384.	0.6	180
108	Homocysteine, Pharmacogenetics, and Neurotoxicity in Children With Leukemia. Journal of Clinical Oncology, 2003, 21, 3084-3091.	0.8	180

#	Article	IF	Citations
109	Challenging issues in pediatric oncology. Nature Reviews Clinical Oncology, 2011, 8, 540-549.	12.5	180
110	Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood, 2008, 112, 4178-4183.	0.6	179
111	Immediate Neurocognitive Effects of Methylphenidate on Learning-Impaired Survivors of Childhood Cancer. Journal of Clinical Oncology, 2001, 19, 1802-1808.	0.8	177
112	Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncology, The, 2015, 16, 465-474.	5.1	177
113	Urate oxidase in the prophylaxis or treatment of hyperuricemia: The United States experience. Seminars in Hematology, 2001, 38, 13-21.	1.8	177
114	Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood, 2012, 120, 468-472.	0.6	176
115	Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood, 2013, 121, 898-904.	0.6	174
116	Favorable Impact of the t(9;11) in Childhood Acute Myeloid Leukemia. Journal of Clinical Oncology, 2002, 20, 2302-2309.	0.8	173
117	Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood, 2002, 100, 2399-2402.	0.6	171
118	Smaller white-matter volumes are associated with larger deficits in attention and learning among long-term survivors of acute lymphoblastic leukemia. Cancer, 2006, 106, 941-949.	2.0	171
119	Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood, 2020, 135, 41-55.	0.6	171
120	Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. Journal of Clinical Oncology, 2019, 37, 3377-3391.	0.8	169
121	ARID5B Genetic Polymorphisms Contribute to Racial Disparities in the Incidence and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2012, 30, 751-757.	0.8	165
122	TOPOISOMERASE II INHIBITOR-RELATED ACUTE MYELOID LEUKAEMIA. British Journal of Haematology, 2000, 109, 13-23.	1.2	164
123	The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real-World Implementation. Clinical Pharmacology and Therapeutics, 2013, 94, 207-210.	2.3	164
124	Lactic acidosis: A metabolic complication of hematologic malignancies. Cancer, 2001, 92, 2237-2246.	2.0	161
125	Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. Lancet Oncology, The, 2015, 16, 1659-1666.	5.1	161
126	Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. Blood, 2009, 113, 5083-5089.	0.6	159

#	Article	IF	Citations
127	Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia. JAMA Oncology, 2020, 6, 358.	3.4	159
128	Human Granulocyte Colony-Stimulating Factor after Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia. New England Journal of Medicine, 1997, 336, 1781-1787.	13.9	158
129	Outcome of childhood acute lymphoblastic leukaemia in resource-poor countries. Lancet, The, 2003, 362, 706-708.	6.3	157
130	High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood, 2011, 118, 223-230.	0.6	157
131	Hypersensitivity or Development of Antibodies to Asparaginase Does Not Impact Treatment Outcome of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2000, 18, 1525-1532.	0.8	155
132	Results of Therapy for Acute Lymphoblastic Leukemia in Black and White Children. JAMA - Journal of the American Medical Association, 2003, 290, 2001.	3.8	155
133	Biology of Childhood Acute Lymphoblastic Leukemia. Pediatric Clinics of North America, 2015, 62, 47-60.	0.9	155
134	Pharmacogenetic Risk Factors for Osteonecrosis of the Hip Among Children With Leukemia. Journal of Clinical Oncology, 2004, 22, 3930-3936.	0.8	152
135	Premature Ovarian Insufficiency in Childhood Cancer Survivors: A Report From the St. Jude Lifetime Cohort. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2242-2250.	1.8	152
136	Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell, 2005, 7, 375-386.	7.7	150
137	Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncology, The, 2019, 20, e142-e154.	5.1	149
138	Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood, 2003, 101, 3862-3867.	0.6	145
139	Central Nervous System Disease in Hematologic Malignancies: Historical Perspective and Practical Applications. Seminars in Oncology, 2009, 36, S2-S16.	0.8	144
140	Acute lymphoblastic leukemia in children. Current Opinion in Oncology, 2000, 12, 3-12.	1.1	143
141	Dexamethasone alters sleep and fatigue in pediatric patients with acute lymphoblastic leukemia. Cancer, 2007, 110, 2321-2330.	2.0	142
142	Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia. Journal of Clinical Oncology, 2011, 29, 3293-3300.	0.8	142
143	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. Cancer Cell, 2018, 33, 937-948.e8.	7.7	142
144	Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood, 2001, 97, 2115-2120.	0.6	140

#	Article	IF	Citations
145	Saving the Children â€" Improving Childhood Cancer Treatment in Developing Countries. New England Journal of Medicine, 2005, 352, 2158-2160.	13.9	137
146	Risk Factors for Traumatic and Bloody Lumbar Puncture in Children With Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2002, 288, 2001.	3.8	136
147	Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nature Medicine, 2011, 17, 1298-1303.	15.2	133
148	Proximal Tubular Secretion of Creatinine by Organic Cation Transporter OCT2 in Cancer Patients. Clinical Cancer Research, 2012, 18, 1101-1108.	3.2	133
149	Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood, 2010, 115, 4657-4663.	0.6	132
150	Somatic and germline genomics in paediatric acute lymphoblastic leukaemia. Nature Reviews Clinical Oncology, 2019, 16, 227-240.	12.5	132
151	Acute leukaemia with mixed lymphoid and myeloid phenotype. British Journal of Haematology, 1984, 56, 121-130.	1.2	129
152	Asparaginase May Influence Dexamethasone Pharmacokinetics in Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2008, 26, 1932-1939.	0.8	129
153	Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. Journal of Clinical Investigation, 2005, 115, 110-117.	3.9	129
154	Sex Differences in Prognosis for Children With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 1999, 17, 818-818.	0.8	128
155	Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia. PLoS Genetics, 2015, 11, e1005262.	1.5	128
156	Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood, 2006, 107, 843-844.	0.6	127
157	Death during induction therapy and first remission of acute leukemia in childhood. Cancer, 2004, 101, 1677-1684.	2.0	126
158	NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nature Genetics, 2015, 47, 607-614.	9.4	126
159	Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood, 2004, 103, 67-72.	0.6	125
160	Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. British Journal of Haematology, 2003, 123, 243-252.	1.2	122
161	Improved Prognosis for Older Adolescents With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2011, 29, 386-391.	0.8	122
162	Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia. Clinical Infectious Diseases, 2018, 67, 541-548.	2.9	122

#	Article	IF	Citations
163	TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. Journal of Clinical Oncology, 2018, 36, 591-599.	0.8	121
164	Typhlitis in childhood cancer. Cancer, 2005, 104, 380-387.	2.0	120
165	Second Malignant Neoplasms After Treatment of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2013, 31, 2469-2476.	0.8	120
166	Improving outcomes for children with cancer in low-income countries in Latin America: A report on the recent meetings of the Monza International School of Pediatric Hematology/Oncology (MISPHO)-Part I. Pediatric Blood and Cancer, 2007, 48, 364-369.	0.8	119
167	Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell, 2016, 29, 186-200.	7.7	118
168	Neuromuscular impairments in adult survivors of childhood acute lymphoblastic leukemia. Cancer, 2012, 118, 828-838.	2.0	117
169	Lessons from the past: Opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies. Pediatric Blood and Cancer, 2012, 58, 334-343.	0.8	116
170	Longitudinal Assessment of Neurocognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia Treated on a Contemporary Chemotherapy Protocol. Journal of Clinical Oncology, 2016, 34, 1239-1247.	0.8	116
171	A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood, 2006, 108, 97-102.	0.6	114
172	Childhood and Adolescent Lymphoid and Myeloid Leukemia. Hematology American Society of Hematology Education Program, 2004, 2004, 118-145.	0.9	111
173	Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy. Journal of Clinical Oncology, 2016, 34, 919-926.	0.8	111
174	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood, 2015, 125, 680-686.	0.6	110
175	Risk factors for hyperglycemia in children with leukemia receiving l-asparaginase and prednisone. Journal of Pediatrics, 1981, 99, 46-50.	0.9	109
176	Biology and treatment of acute lymphoblastic leukemia. Journal of Pediatrics, 1994, 124, 491-503.	0.9	109
177	Obesity in Survivors of Childhood Acute Lymphoblastic Leukemia and Lymphoma. Journal of Clinical Oncology, 2007, 25, 1183-1189.	0.8	109
178	Early complications in children with acute lymphoblastic leukemia presenting with hyperleukocytosis. Pediatric Blood and Cancer, 2005, 45, 10-15.	0.8	106
179	Minimal residual diseaseâ€“guided therapy in childhood acute lymphoblastic leukemia. Blood, 2017, 129, 1913-1918.	0.6	106
180	Reduced Folate Carrier Expression in Acute Lymphoblastic Leukemia: A Mechanism for Ploidy but not Lineage Differences in Methotrexate Accumulation. Blood, 1999, 93, 1643-1650.	0.6	105

#	Article	IF	Citations
181	Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP. Genome Research, 2017, 27, 185-195.	2.4	105
182	Genetic Risk for Subsequent Neoplasms Among Long-Term Survivors of Childhood Cancer. Journal of Clinical Oncology, 2018, 36, 2078-2087.	0.8	105
183	A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood, 2007, 110, 1271-1277.	0.6	104
184	A Prospective Cohort Study of Late Sequelae of Pediatric Allogeneic Hematopoietic Stem Cell Transplantation. Medicine (United States), 2007, 86, 215-224.	0.4	104
185	Treatment Outcomes in Black and White Children With Cancer: Results From the SEER Database and St Jude Children's Research Hospital, 1992 Through 2007. Journal of Clinical Oncology, 2012, 30, 2005-2012.	0.8	104
186	Chemotherapy Pharmacodynamics and Neuroimaging and Neurocognitive Outcomes in Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2016, 34, 2644-2653.	0.8	104
187	Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood, 2012, 120, 4197-4204.	0.6	103
188	Childhood Acute Lymphoblastic Leukemia With the MLL-ENL Fusion and t(11;19)(q23;p13.3) Translocation. Journal of Clinical Oncology, 1999, 17, 191-191.	0.8	102
189	Central Nervous System Disease in Acute Lymphoblastic Leukemia: Prophylaxis and Treatment. Hematology American Society of Hematology Education Program, 2006, 2006, 142-146.	0.9	102
190	Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. Blood, 2015, 126, 1770-1776.	0.6	102
191	Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood, 2006, 108, 1050-1057.	0.6	98
192	Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis. Lancet Haematology,the, 2016, 3, e456-e466.	2.2	96
193	Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. Journal of Pediatrics, 1987, 111, 606-612.	0.9	95
194	Differences in Folylpolyglutamate Synthetase and Dihydrofolate Reductase Expression in Human B-Lineage versus T-Lineage Leukemic Lymphoblasts: Mechanisms for Lineage Differences in Methotrexate Polyglutamylation and Cytotoxicity. Molecular Pharmacology, 1997, 52, 155-163.	1.0	95
195	Rasburicase: a potent uricolytic agent. Expert Opinion on Pharmacotherapy, 2002, 3, 433-442.	0.9	95
196	Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia. Journal of Clinical Oncology, 2016, 34, 4094-4101.	0.8	93
197	Mutational Landscape and Patterns of Clonal Evolution in Relapsed Pediatric Acute Lymphoblastic Leukemia. Blood Cancer Discovery, 2020, 1, 96-111.	2.6	93
198	Hyperdiploid Acute Lymphoblastic Leukemia With 51 to 65 Chromosomes: A Distinct Biological Entity With a Marked Propensity to Undergo Apoptosis. Blood, 1999, 93, 315-320.	0.6	92

#	Article	IF	Citations
199	Acute Lymphoblastic Leukemia. Hematology American Society of Hematology Education Program, 2002, 2002, 162-192.	0.9	92
200	Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics and Genomics, 2002, 12, 605-611.	5.7	92
201	Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia. Cancer, 2003, 98, 2715-2722.	2.0	92
202	Clinical and diagnostic imaging findings predict anesthetic complications in children presenting with malignant mediastinal masses. Paediatric Anaesthesia, 2007, 17, 070615191839005-???.	0.6	92
203	The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort Study. Lancet Haematology,the, 2019, 6, e306-e316.	2.2	92
204	Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncology, The, 2020, 21, 551-560.	5.1	92
205	Case-Control Study Suggests a Favorable Impact of TEL Rearrangement in Patients With B-Lineage Acute Lymphoblastic Leukemia Treated With Antimetabolite-Based Therapy: A Pediatric Oncology Group Study. Blood, 1997, 89, 1143-1146.	0.6	91
206	Outcomes of Growth Hormone Replacement Therapy in Survivors of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2002, 20, 2959-2964.	0.8	90
207	ALK-Positive Anaplastic Large Cell Lymphoma With Leukemic Peripheral Blood Involvement Is a Clinicopathologic Entity With an Unfavorable Prognosis. American Journal of Clinical Pathology, 2003, 120, 617-625.	0.4	90
208	Femoral Head Osteonecrosis in Pediatric and Young Adult Patients With Leukemia or Lymphoma. Journal of Clinical Oncology, 2007, 25, 1525-1531.	0.8	90
209	Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry. Blood, 2017, 130, 1209-1212.	0.6	90
210	Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia.. Journal of Clinical Oncology, 1998, 16, 3768-3773.	0.8	89
211	Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood, 2006, 108, 3997-4002.	0.6	89
212	Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2016, 34, 2133-2140.	0.8	88
213	Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing. Cancer Discovery, 2021, 11, 3008-3027.	7.7	88
214	De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood, 2002, 100, 1240-1247.	0.6	87
215	Premedication with acetaminophen or diphenhydramine for transfusion with leucoreduced blood products in children. British Journal of Haematology, 2005, 130, 781-787.	1.2	87
216	Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer, 2008, 113, 376-382.	2.0	87

#	Article	IF	Citations
217	Evaluation of Memory Impairment in Aging Adult Survivors of Childhood Acute Lymphoblastic Leukemia Treated With Cranial Radiotherapy. Journal of the National Cancer Institute, 2013, 105, 899-907.	3.0	86
218	Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia. Journal of Clinical Medicine, 2021, 10, 1926.	1.0	86
219	Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood, 2006, 108, 3302-3304.	0.6	85
220	Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer, 2007, 109, 157-163.	2.0	85
221	Validity and Reliability of a New Instrument to Measure Cancer-Related Fatigue in Adolescents. Journal of Pain and Symptom Management, 2007, 34, 607-618.	0.6	85
222	Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. American Journal of Neuroradiology, 2005, 26, 1263-9.	1.2	85
223	HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood, 2014, 124, 1266-1276.	0.6	84
224	Philadelphia Chromosomeâ€“like Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 464-470.	0.2	84
225	Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Reviews, 2002, 16, 225-243.	2.8	83
226	A substrate specific functional polymorphism of human Î³-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. Pharmacogenetics and Genomics, 2004, 14, 557-567.	5.7	83
227	Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. Cancer, 2008, 113, 522-529.	2.0	83
228	Global efforts toward the cure of childhood acute lymphoblastic leukaemia. The Lancet Child and Adolescent Health, 2018, 2, 440-454.	2.7	83
229	Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia. Cancer Discovery, 2021, 11, 2846-2867.	7.7	83
230	Evans syndrome in childhood. Journal of Pediatrics, 1980, 97, 754-758.	0.9	82
231	Cognitive, behaviour, and academic functioning in adolescent and young adult survivors of childhood acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study. Lancet Psychiatry,the, 2016, 3, 965-972.	3.7	82
232	Outcome of Treatment for Childhood Cancer in Black as Compared With White Children. JAMA - Journal of the American Medical Association, 1995, 273, 633.	3.8	81
233	Recent Research Advances in Childhood Acute Lymphoblastic Leukemia. Journal of the Formosan Medical Association, 2010, 109, 777-787.	0.8	81
234	Genetic Mediators of Neurocognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2013, 31, 2182-2188.	0.8	80

#	Article	IF	Citations
235	Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer, 2005, 103, 368-376.	2.0	79
236	Prospective Analysis of TEL Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. Journal of Clinical Oncology, 2008, 26, 2186-2191.	0.8	79
237	Changes in bone mineral density in survivors of childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2006, 46, 77-87.	0.8	78
238	Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood, 2012, 119, 1658-1664.	0.6	77
239	Systematic review and metaâ€analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2013, 60, 185-195.	0.8	77
240	Association Between Anesthesia Exposure and Neurocognitive and Neuroimaging Outcomes in Long-term Survivors of Childhood Acute Lymphoblastic Leukemia. JAMA Oncology, 2019, 5, 1456.	3.4	77
241	Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. Blood, 2015, 126, 2896-2899.	0.6	76
242	In Vivo Response to Methotrexate Forecasts Outcome of Acute Lymphoblastic Leukemia and Has a Distinct Gene Expression Profile. PLoS Medicine, 2008, 5, e83.	3.9	75
243	Attention and working memory abilities in children treated for acute lymphoblastic leukemia. Cancer, 2010, 116, 4638-4645.	2.0	74
244	Impact of sleep, fatigue, and systemic inflammation on neurocognitive and behavioral outcomes in longâ€term survivors of childhood acute lymphoblastic leukemia. Cancer, 2017, 123, 3410-3419.	2.0	74
245	A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. , 2019, 7, 81.		74
246	Precision medicine in acute lymphoblastic leukemia. Frontiers of Medicine, 2020, 14, 689-700.	1.5	74
247	Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nature Genetics, 2005, 37, 878-882.	9.4	72
248	Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. Nature Communications, 2015, 6, 7553.	5.8	72
249	Global Pediatric Oncology: Lessons From Partnerships Between High-Income Countries and Low- to Mid-Income Countries. Journal of Clinical Oncology, 2016, 34, 53-61.	0.8	72
250	Clinical implications and surgical management of intussusception in pediatric patients with Burkitt lymphoma. Journal of Pediatric Surgery, 2007, 42, 998-1001.	0.8	71
251	Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2011, 57, 1147-1153.	0.8	71
252	Energy balance and fitness in adult survivors of childhood acute lymphoblastic leukemia. Blood, 2015, 125, 3411-3419.	0.6	71

#	Article	IF	Citations
253	Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Diseaseâ€"Directed Therapy. Blood Cancer Discovery, 2021, 2, 326-337.	2.6	71
254	SEIZURES IN CHILDHOOD LYMPHOBLASTIC LEUKAEMIA PATIENTS. Lancet, The, 1984, 324, 1422-1424.	6.3	70
255	Risk of Adverse Events After Completion of Therapy for Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2005, 23, 7936-7941.	0.8	70
256	Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. Lancet Oncology, The, 2013, 14, e508-e523.	5.1	70
257	Skeletal, neuromuscular and fitness impairments among children with newly diagnosed acute lymphoblastic leukemia. Leukemia and Lymphoma, 2015, 56, 1004-1011.	0.6	70
258	Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nature Cancer, 2021, 2, 284-299.	5.7	70
259	Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia. JAMA Oncology, 2018, 4, 1413.	3.4	69
260	Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia. European Journal of Cancer, 2014, 50, 2685-2694.	1.3	67
261	Interim Comparison of a Continuous Infusion Versus a Short Daily Infusion of Cytarabine Given in Combination With Cladribine for Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology, 2002, 20, 4217-4224.	0.8	65
262	Immunotherapy in pediatric acute lymphoblastic leukemia. Cancer and Metastasis Reviews, 2019, 38, 595-610.	2.7	65
263	Acute megakaryoblastic leukaemia associated with intrinsic platelet dysfunction and constitutional ring 21 chromosome in a young boy. British Journal of Haematology, 1982, 50, 191-200.	1.2	64
264	Efficacy of Glucarpidase (Carboxypeptidase <scp>G</scp>2) in Patients with Acute Kidney Injury After Highâ€Dose Methotrexate Therapy. Pharmacotherapy, 2014, 34, 427-439.	1.2	64
265	Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. Blood, 2015, 126, 69-75.	0.6	64
266	Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study. Journal of Clinical Oncology, 2019, 37, 770-779.	0.8	64
267	Acute Leukemias with the t(4;11)(q21;q23). Leukemia and Lymphoma, 1992, 7, 173-179.	0.6	63
268	Resumption of highâ€dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer, 2012, 118, 4321-4330.	2.0	62
269	Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia. Clinical Infectious Diseases, 2017, 65, 1790-1798.	2.9	62
270	MicroRNAs Form Triplexes with Double Stranded DNA at Sequence-Specific Binding Sites; a Eukaryotic Mechanism via which microRNAs Could Directly Alter Gene Expression. PLoS Computational Biology, 2016, 12, e1004744.	1.5	62

#	Article	IF	Citations
271	High-dose methotrexate improves clinical outcome in children with acute lymphoblastic leukemia: St. Jude total therapy study X. Medical and Pediatric Oncology, 1988, 16, 297-303.	1.0	61
272	Secondary chromosomal abnormalities predict outcome in pediatric and adult high-stage Burkitt lymphoma. Cancer, 2006, 107, 1084-1092.	2.0	61
273	Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. Journal of Clinical Oncology, 2019, 37, 2051-2061.	0.8	61
274	ACUTE LYMPHOBLASTIC LEUKEMIA. Pediatric Clinics of North America, 1997, 44, 831-846.	0.9	60
275	High-Risk Pediatric Acute Lymphoblastic Leukemia: To Transplant or Not to Transplant?. Biology of Blood and Marrow Transplantation, 2011, 17, S137-S148.	2.0	60
276	Universal monitoring of minimal residual disease in acute myeloid leukemia. JCI Insight, 2018, 3, .	2.3	60
277	Reduced Morbidity and Mortality in Survivors of Childhood Acute Lymphoblastic Leukemia: A Report From the Childhood Cancer Survivor Study. Journal of Clinical Oncology, 2020, 38, 3418-3429.	0.8	60
278	Second malignancy after treatment of childhood non-Hodgkin lymphoma. Cancer, 2001, 92, 1959-1966.	2.0	59
279	Immunoregulatory abnormalities in evans syndrome. American Journal of Hematology, 1983, 15, 381-390.	2.0	58
280	Diabetic ketoacidosis during therapy for pediatric acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2008, 50, 1207-1212.	0.8	58
281	Thrombolytic therapy for central venous catheter occlusion. Haematologica, 2012, 97, 641-650.	1.7	58
282	Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosomeâ€positive acute lymphoblastic leukemia. Cancer, 2014, 120, 1514-1519.	2.0	58
283	Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk. Nature Communications, 2019, 10, 5348.	5.8	58
284	ELECTIVE TESTICULAR BIOPSY DURING CHEMOTHERAPY FOR CHILDHOOD LEUKAEMIA IS OF NO CLINICAL VALUE. Lancet, The, 1985, 326, 410-412.	6.3	57
285	Epidural spinal cord compression as the initial finding in childhood acute leukemia and non-Hodgkin lymphoma. Journal of Pediatrics, 1985, 106, 788-792.	0.9	57
286	Urate oxidase in the prophylaxis or treatment of hyperuricemia: The United States experience. Seminars in Hematology, 2001, 38, 13-21.	1.8	57
287	Toward Optimal Central Nervous Systemâ€“Directed Treatment in Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2003, 21, 179-181.	0.8	57
288	PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Human Molecular Genetics, 2012, 21, 4793-4804.	1.4	56

#	Article	IF	Citations
289	Effect of body mass index on the outcome of children with acute myeloid leukemia. Cancer, 2012, 118, 5989-5996.	2.0	56
290	Utility of Early Screening Magnetic Resonance Imaging for Extensive Hip Osteonecrosis in Pediatric Patients Treated With Glucocorticoids. Journal of Clinical Oncology, 2015, 33, 610-615.	0.8	56
291	Treatment abandonment in childhood acute lymphoblastic leukaemia in China: a retrospective cohort study of the Chinese Childrenâ€™s Cancer Group. Archives of Disease in Childhood, 2019, 104, 522-529.	1.0	55
292	Hypothalamic-Pituitary Disorders in Childhood Cancer Survivors: Prevalence, Risk Factors and Long-Term Health Outcomes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6101-6115.	1.8	54
293	Childhood acute lymphoblastic leukemia. Reviews in Clinical and Experimental Hematology, 2002, 6, 161-180.	0.1	53
294	Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood, 2005, 106, 1778-1785.	0.6	53
295	Pulmonary dysfunction in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem cell transplantation. Cancer, 2010, 116, 2020-2030.	2.0	53
296	Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. Cancer, 2014, 120, 1985-1992.	2.0	53
297	The relationship of blast cell glucocorticoid receptor levels to response to single-agent steroid trial and remission response in children with acute lymphoblastic leukemia. Leukemia Research, 1984, 8, 579-585.	0.4	52
298	Impact of age on outcome of pediatric acute myeloid leukemia. Cancer, 2006, 106, 2495-2502.	2.0	52
299	Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood, 2009, 113, 4512-4520.	0.6	52
300	Longitudinal Changes in Body Mass and Composition in Survivors of Childhood Hematologic Malignancies After Allogeneic Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2012, 30, 3991-3997.	0.8	52
301	Long-term decline in intelligence among adult survivors of childhood acute lymphoblastic leukemia treated with cranial radiation. Blood, 2013, 122, 550-553.	0.6	52
302	Acute lymphoblastic leukemia: A populationâ€based study of outcome in the <scp>U</scp>nited <scp>S</scp>tates based on the surveillance, epidemiology, and end results (<scp>SEER</scp>) database, <scp>1980</scp>â€“<scp>2017</scp>. American Journal of Hematology, 2021, 96, 650-658.	2.0	52
303	Juvenile Myelomonocytic Leukemia. Blood, 1997, 90, 479-488.	0.6	52
304	Azithromycin for treatment of severe Cryptosporidium diarrhea in two children with cancer. Journal of Pediatrics, 1993, 123, 154-156.	0.9	51
305	Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. Pediatric Blood and Cancer, 2006, 47, 931-935.	0.8	51
306	Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae. Neuroradiology, 2007, 49, 873-888.	1.1	51

#	Article	IF	Citations
307	High-Risk Childhood Acute Lymphoblastic Leukemia. Clinical Lymphoma and Myeloma, 2009, 9, S222-S230.	1.4	50
308	Nutritional intake of longâ€term survivors of childhood acute lymphoblastic leukemia: Evidence for bone health interventional opportunities. Pediatric Blood and Cancer, 2010, 55, 1362-1369.	0.8	50
309	PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. Blood, 2018, 131, 2256-2261.	0.6	49
310	Avascular femoral head necrosis in pediatric cancer patients. Medical and Pediatric Oncology, 1993, 21, 655-660.	1.0	48
311	International Collaboration on Childhood Leukemia. International Journal of Hematology, 2003, 78, 383-389.	0.7	48
312	CRHR1 Polymorphisms Predict Bone Density in Survivors of Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2008, 26, 3031-3037.	0.8	48
313	Dexamethasone exposure and memory function in adult survivors of childhood acute lymphoblastic leukemia: A report from the SJLIFE cohort. Pediatric Blood and Cancer, 2013, 60, 1778-1784.	0.8	48
314	Feasibility and Initial Effectiveness of Home Exercise During Maintenance Therapy for Childhood Acute Lymphoblastic Leukemia. Pediatric Physical Therapy, 2014, 26, 301-307.	0.3	48
315	Vertebral compression fracture as a presenting feature of acute lymphoblastic leukemia in children. Cancer, 1988, 61, 589-592.	2.0	47
316	Clofarabine. Nature Reviews Drug Discovery, 2005, 4, 369-370.	21.5	47
317	Recurrent intrathecal methotrexate induced neurotoxicity in an adolescent with acute lymphoblastic leukemia: Serial clinical and radiologic findings. Pediatric Blood and Cancer, 2009, 52, 293-295.	0.8	47
318	Unusual extramedullary relapses in children with acute lymphoblastic leukemia. Journal of Pediatrics, 1986, 109, 665-668.	0.9	46
319	Intrauterine monoclonal origin of neonatal concordant acute lymphoblastic leukemia in monozygotic twins. Medical and Pediatric Oncology, 1995, 24, 77-81.	1.0	46
320	Cyclosporin A Induces Apoptosis in Childhood Acute Lymphoblastic Leukemia Cells. Blood, 1998, 91, 1001-1007.	0.6	46
321	HPLC Determination of Thiopurine Nucleosides and Nucleotides in Vivo in Lymphoblasts following Mercaptopurine Therapy. Clinical Chemistry, 2002, 48, 61-68.	1.5	46
322	Natural history of thyroid nodules in survivors of pediatric Hodgkin lymphoma. Pediatric Blood and Cancer, 2006, 46, 314-319.	0.8	46
323	Effect of race on outcome of white and black children with acute myeloid leukemia: The St. Jude experience. Pediatric Blood and Cancer, 2007, 48, 10-15.	0.8	46
324	Modeling Mechanisms of In Vivo Variability in Methotrexate Accumulation and Folate Pathway Inhibition in Acute Lymphoblastic Leukemia Cells. PLoS Computational Biology, 2010, 6, e1001019.	1.5	46

#	Article	IF	Citations
325	Acute respiratory infections in children and adolescents with acute lymphoblastic leukemia. Cancer, 2016, 122, 798-805.	2.0	46
326	Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation. Blood, 2021, 138, 331-343.	0.6	46
327	Bone marrow necrosis in children with malignant disease. Cancer, 1985, 56, 1522-1525.	2.0	45
328	Hypersensitivity reactions to epipodophyllotoxins in children with acute lymphoblastic leukemia. Cancer, 1991, 67, 1070-1075.	2.0	45
329	Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. Blood, 2002, 100, 43-47.	0.6	45
330	Shortening Infusion Time for High-Dose Methotrexate Alters Antileukemic Effects: A Randomized Prospective Clinical Trial. Journal of Clinical Oncology, 2011, 29, 1771-1778.	0.8	45
331	Central precocious puberty following the diagnosis and treatment of paediatric cancer and central nervous system tumours: presentation and longâ€term outcomes. Clinical Endocrinology, 2016, 84, 361-371.	1.2	45
332	Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia. Best Practice and Research in Clinical Haematology, 2002, 15, 741-756.	0.7	44
333	Viridans Streptococcal Sepsis: Clinical Features and Complications in Childhood Acute Myeloid Leukemia. Journal of Pediatric Hematology/Oncology, 2003, 25, 696-703.	0.3	44
334	Near-triploidy and near-tetraploidy in childhood acute lymphoblastic leukemia: association with B-lineage blast cells carrying the ETV6â€“RUNX1 fusion, T-lineage immunophenotype, and favorable outcome. Cancer Genetics and Cytogenetics, 2006, 169, 50-57.	1.0	44
335	Effect of Race on the Outcome of Pediatric Patients With Hodgkin's Lymphoma. Journal of Clinical Oncology, 2008, 26, 1282-1288.	0.8	44
336	A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology. Nature Communications, 2016, 7, 10635.	5.8	44
337	Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. Blood, 2019, 133, 724-729.	0.6	44
338	Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nature Cancer, 2020, 1, 329-344.	5.7	44
339	A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. Cancer Chemotherapy and Pharmacology, 2002, 50, 419-428.	1.1	43
340	Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia. Cancer Treatment Reviews, 2003, 29, 31-44.	3.4	43
341	Relationships Among Severity of Osteonecrosis, Pain, Range of Motion, and Functional Mobility in Children, Adolescents, and Young Adults With Acute Lymphoblastic Leukemia. Physical Therapy, 2008, 88, 341-350.	1.1	43
342	Neurologic morbidity and quality of life in survivors of childhood acute lymphoblastic leukemia: a prospective cross-sectional study. Journal of Cancer Survivorship, 2014, 8, 688-696.	1.5	43

#	Article	IF	Citations
343	Changes in body mass index, height, and weight in children during and after therapy for acute lymphoblastic leukemia. Cancer, 2018, 124, 4248-4259.	2.0	43
344	Lack of pathogenetic role of proteins C and S in thrombosis associated with asparaginase-prednisone-vincristine therapy for leukaemia. British Journal of Haematology, 1986, 64, 283-290.	1.2	42
345	Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia. Pharmacogenetics and Genomics, 2008, 18, 507-514.	0.7	42
346	Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncology, The, 2021, 22, 1322-1332.	5.1	42
347	Unfavorable presenting clinical and laboratory features are associated with calla-negative non-t, non-b lymphoblastic leukemia in children. Leukemia Research, 1986, 10, 1287-1292.	0.4	41
348	MRI of Knee Osteonecrosis in Children with Leukemia and Lymphoma: Part 2, Clinical and Imaging Patterns. American Journal of Roentgenology, 2006, 186, 477-482.	1.0	41
349	Acute Lymphoblastic Leukemia: Introduction. Seminars in Hematology, 2009, 46, 1-2.	1.8	41
350	Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer, 2013, 119, 4036-4043.	2.0	41
351	Renal dysfunction and hyperuricemia at presentation and relapse of acute lymphoblastic leukemia. Medical and Pediatric Oncology, 1990, 18, 283-286.	1.0	40
352	Association of Cerebrospinal Fluid Biomarkers of Central Nervous System Injury With Neurocognitive and Brain Imaging Outcomes in Children Receiving Chemotherapy for Acute Lymphoblastic Leukemia. JAMA Oncology, 2018, 4, e180089.	3.4	40
353	Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group. Leukemia, 2021, 35, 3272-3277.	3.3	40
354	Involvement of von willebrand factor in thrombosis following asparaginase-prednisone-vincristine therapy for leukemia. American Journal of Hematology, 1987, 25, 291-298.	2.0	39
355	White Race As a Risk Factor for Hypothyroidism After Treatment for Pediatric Hodgkin's Lymphoma. Journal of Clinical Oncology, 2006, 24, 1516-1521.	0.8	39
356	Differential Effects of Targeted Disruption of Thiopurine Methyltransferase on Mercaptopurine and Thioguanine Pharmacodynamics. Cancer Research, 2007, 67, 4965-4972.	0.4	39
357	Natural killer cell therapy in children with relapsed leukemia. Pediatric Blood and Cancer, 2015, 62, 1468-1472.	0.8	39
358	Modifiable Factors Associated With Aging Phenotypes Among Adult Survivors of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2016, 34, 2509-2515.	0.8	39
359	Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis. Blood, 2004, 104, 1435-1441.	0.6	38
360	Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28040.	0.8	38

#	Article	IF	Citations
361	Prevalence and Growth Characteristics of Malignant Stem Cells in B-Lineage Acute Lymphoblastic Leukemia. Blood, 1997, 89, 3735-3744.	0.6	38
362	Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity. Clinical Cancer Research, 2002, 8, 2423-9.	3.2	38
363	Cerebrospinal Fluid Asparagine Concentrations After Escherichia coli Asparaginase in Children With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 1999, 17, 1568-1568.	0.8	37
364	Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation. British Journal of Haematology, 2012, 156, 109-117.	1.2	37
365	Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome. Blood, 2019, 134, 1227-1237.	0.6	37
366	Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia. Blood, 2021, 137, 364-373.	0.6	37
367	A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL). Blood, 2011, 118, 248-248.	0.6	37
368	Recombinant Urate Oxidase for Prevention of Hyperuricemia and Tumor Lysis Syndrome in Lymphoid Malignancies. Clinical Lymphoma and Myeloma, 2003, 3, 225-232.	2.1	36
369	Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. Cancer Chemotherapy and Pharmacology, 2013, 72, 369-378.	1.1	36
370	NK Cell Genotype and Phenotype at Diagnosis of Acute Lymphoblastic Leukemia Correlate with Postinduction Residual Disease. Clinical Cancer Research, 2014, 20, 5986-5994.	3.2	36
371	CNS Involvement in Children With Newly Diagnosed Non-Hodgkinâ€™s Lymphoma. Journal of Clinical Oncology, 2000, 18, 3018-3024.	0.8	35
372	Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia. Pediatric Blood and Cancer, 2005, 44, 63-69.	0.8	35
373	Recent advances in genetic predisposition to pediatric acute lymphoblastic leukemia. Expert Review of Hematology, 2020, 13, 55-70.	1.0	35
374	Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia. JAMA Oncology, 2022, 8, 354.	3.4	35
375	Pharmacokinetics and Pharmacodynamics of Oral Etoposide in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2003, 21, 1340-1346.	0.8	34
376	A sustainable model for pediatric oncology nursing education in lowâ€income countries. Pediatric Blood and Cancer, 2012, 58, 163-166.	0.8	34
377	Decreased relapsed rate and treatmentâ€related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials. Cancer, 2017, 123, 3791-3798.	2.0	34
378	Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial. Journal of Clinical Oncology, 2019, 37, 2072-2081.	0.8	34

#	Article	IF	Citations
379	Leydig Cell Function in Male Survivors of Childhood Cancer: A Report From the St Jude Lifetime Cohort Study. Journal of Clinical Oncology, 2019, 37, 3018-3031.	0.8	34
380	Prophylaxis ofPneumocystis carinii pneumonia with atovaquone in children with leukemia. Cancer, 2007, 109, 1654-1658.	2.0	33
381	Implementation of a data management program in a pediatric cancer unit in a low income country. Pediatric Blood and Cancer, 2007, 49, 23-27.	0.8	33
382	Prognostic Importance of 6-Mercaptopurine Dose Intensity in Acute Lymphoblastic Leukemia. Blood, 1999, 93, 2817-2823.	0.6	33
383	Cyclic combination chemotherapy for acute lymphoblastic leukemia recurring after elective cessation of therapy. Medical and Pediatric Oncology, 1988, 16, 21-26.	1.0	32
384	Vincristine-induced vocal cord paralysis in an infant. Paediatric Anaesthesia, 2002, 12, 168-170.	0.6	32
385	Strategies to improve outcomes of children with cancer in low-income countries. European Journal of Cancer, 2005, 41, 1584-1587.	1.3	32
386	Epigenetic Regulation of Human Î³-Glutamyl Hydrolase Activity in Acute Lymphoblastic Leukemia Cells. American Journal of Human Genetics, 2006, 79, 264-274.	2.6	32
387	Risk-adapted Treatment of Pediatric Acute Lymphoblastic Leukemia. Hematology/Oncology Clinics of North America, 2009, 23, 973-990.	0.9	32
388	The controversy of varicella vaccination in children with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2012, 58, 12-16.	0.8	32
389	Treatment outcome in older patients with childhood acute myeloid leukemia. Cancer, 2012, 118, 6253-6259.	2.0	32
390	Whole-genome noncoding sequence analysis in T-cell acute lymphoblastic leukemia identifies oncogene enhancer mutations. Blood, 2017, 129, 3264-3268.	0.6	32
391	Brain Network Connectivity and Executive Function in Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia. Brain Connectivity, 2018, 8, 333-342.	0.8	32
392	Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute Lymphoblastic Leukemia in Children. Journal of the National Cancer Institute, 2019, 111, 1350-1357.	3.0	32
393	A quantitative MR imaging assessment of leukoencephalopathy in children treated for acute lymphoblastic leukemia without irradiation. American Journal of Neuroradiology, 2005, 26, 2371-7.	1.2	32
394	Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy. British Journal of Haematology, 2015, 168, 94-101.	1.2	31
395	Disseminated fusariosis involving bone in an adolescent with leukemia. Pediatric Infectious Disease Journal, 1992, 11, 965-968.	1.1	30
396	Acute leukemia in children. Current Opinion in Hematology, 1996, 3, 249-258.	1.2	30

#	Article	IF	Citations
397	Late-onset delayed excretion of methotrexate. Cancer Chemotherapy and Pharmacology, 2004, 54, 146-52.	1.1	30
398	Lymphoid gene expression as a predictor of risk of secondary brain tumors. Genes Chromosomes and Cancer, 2005, 42, 107-116.	1.5	30
399	Evolution of neurocognitive function in long-term survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. Journal of Cancer Survivorship, 2018, 12, 398-406.	1.5	30
400	Peripheral Neuropathy, Sensory Processing, and Balance in Survivors of Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2018, 36, 2315-2322.	0.8	30
401	Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline. Journal of Clinical Oncology, 2019, 37, 239-253.	0.8	30
402	The Role of Leukapheresis in the Current Management of Hyperleukocytosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia. Pediatric Blood and Cancer, 2016, 63, 1546-1551.	0.8	29
403	Next-Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia. Journal of Pediatrics, 2018, 203, 14-24.e2.	0.9	29
404	Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation. Nature Genetics, 2022, 54, 170-179.	9.4	29
405	Epipodophyllotoxins in the treatment of childhood cancer. Cancer Chemotherapy and Pharmacology, 1994, 34, S89-S95.	1.1	28
406	All children have a right to full access to treatment for cancer. Lancet, The, 2004, 364, 1121-1122.	6.3	28
407	Comparison of treatment outcomes of childhood Hodgkin lymphoma in two US centers and a center in Recife, Brazil. Pediatric Blood and Cancer, 2007, 49, 139-144.	0.8	28
408	Evidence for Age As a Modifier of Genetic Associations for Lipid Levels. Annals of Human Genetics, 2011, 75, 589-597.	0.3	28
409	Pulmonary Function after Treatment for Childhood Cancer. A Report from the St. Jude Lifetime Cohort Study (SJLIFE). Annals of the American Thoracic Society, 2016, 13, 1575-1585.	1.5	28
410	Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. Blood, 2022, 139, 1785-1793.	0.6	28
411	ARID5B Regulates Leukemia Sensitivity to Antimetabolites in Children with Acute Lymphoblastic Leukemia Via Effects on Cell Cycle Progression. Blood, 2014, 124, 791-791.	0.6	28
412	Impact of treatment efficacy on the prognostic value of glucocorticoid receptor levels in childhood acute lymphoblastic leukemia. Leukemia Research, 1984, 8, 345-350.	0.4	27
413	Acute Lymphoblastic Leukemia in Infants. Journal of Clinical Oncology, 1999, 17, 438-438.	0.8	27
414	Recombinant Urate Oxidase (Rasburicase) in the Prophylaxis and Treatment of Tumor Lysis Syndrome. , 2004, 147, 69-79.		27

#	Article	IF	Citations
415	Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics, 2011, 12, 327-339.	0.6	27
416	Population PK/PD Model of Homocysteine Concentrations after High-Dose Methotrexate Treatment in Patients with Acute Lymphoblastic Leukemia. PLoS ONE, 2012, 7, e46015.	1.1	27
417	Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia. Cancer, 2013, 119, 2061-2066.	2.0	27
418	Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy. Health Physics, 2014, 106, 229-246.	0.3	27
419	Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia. Frontiers of Medicine, 2015, 9, 1-9.	1.5	27
420	Epipodophyllotoxin-related acute myeloid leukaemia. Lancet, The, 1991, 338, 1468.	6.3	25
421	Quantitative morphologic evaluation of magnetic resonance imaging during and after treatment of childhood leukemia. Neuroradiology, 2007, 49, 889-904.	1.1	25
422	Progress in the treatment of adolescents with acute lymphoblastic leukemia. Cancer, 1993, 71, 3400-3405.	2.0	24
423	Continuous infusion of interleukin-2 in children with refractory malignancies. Cancer, 1993, 72, 623-628.	2.0	24
424	A revised classification scheme for acute transfusion reactions. Transfusion, 2007, 47, 621-628.	0.8	24
425	Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. Cancer, 2010, 116, 98-105.	2.0	24
426	Effect of cranial irradiation on sperm concentration of adult survivors of childhood acute lymphoblastic leukemia: a report from the St. Jude Lifetime Cohort Studyâ€. Human Reproduction, 2017, 32, 1192-1201.	0.4	24
427	Child symptoms, parent behaviors, and family strain in longâ€term survivors of childhood acute lymphoblastic leukemia. Psycho-Oncology, 2018, 27, 2031-2038.	1.0	24
428	Impact of ovarian transposition before pelvic irradiation on ovarian function among longâ€term survivors of childhood Hodgkin lymphoma: A report from the St. Jude Lifetime Cohort Study. Pediatric Blood and Cancer, 2018, 65, e27232.	0.8	24
429	Management of anorectal/perineal infections caused by Pseudomonas aeruginosa in children with malignant diseases. Journal of Pediatric Surgery, 1991, 26, 487-493.	0.8	23
430	Physical fitness and neurocognitive outcomes in adult survivors of childhood acute lymphoblastic leukemia: A report from the St. Jude Lifetime cohort. Cancer, 2020, 126, 640-648.	2.0	23
431	Sequential studies of lymphoblast glucocorticoid receptor levels at diagnosis and relapse in childhood leukemia: An update. Leukemia Research, 1986, 10, 227-229.	0.4	22
432	Cholelithiasis after treatment for childhood cancer. Cancer, 1991, 67, 1439-1442.	2.0	22

#	Article	IF	Citations
433	Parvovirus B19 Infection in a Child With Acute Lymphoblastic Leukemia During Induction Therapy. The American Journal of Pediatric Hematology/oncology, 2001, 23, 309-311.	1.3	22
434	Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse. Cancer, 2008, 112, 1983-1991.	2.0	22
435	Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia. Pediatric Blood and Cancer, 2013, 60, 1161-1164.	0.8	22
436	Brain Activity Associated With Attention Deficits Following Chemotherapy for Childhood Acute Lymphoblastic Leukemia. Journal of the National Cancer Institute, 2019, 111, 201-209.	3.0	22
437	Somnolence, hypotension, and metabolic acidosis following high-dose teniposide treatment in children with leukemia. Cancer Chemotherapy and Pharmacology, 1991, 29, 150-154.	1.1	21
438	Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia. Journal of Pharmacokinetics and Pharmacodynamics, 2002, 29, 171-188.	0.8	21
439	Clinical and bilogical characteristics of acute lymphocytic leukemia in children with Down syndrome. American Journal of Medical Genetics Part A, 2005, 37, 267-271.	2.4	21
440	Proxy assessment of quality of life in pediatric clinical trials: Application of the Health Utilities Index 3. Quality of Life Research, 2005, 14, 1045-1056.	1.5	21
441	KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemia. Blood, 2006, 107, 1238-1239.	0.6	21
442	Behavioral symptoms and psychiatric disorders in child and adolescent longâ€term survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. Psycho-Oncology, 2018, 27, 1597-1607.	1.0	21
443	Bone mineral density in children with acute lymphoblastic leukemia. Cancer, 2018, 124, 1025-1035.	2.0	21
444	Association of Bacteremic Sepsis With Long-term Neurocognitive Dysfunction in Pediatric Patients With Acute Lymphoblastic Leukemia. JAMA Pediatrics, 2018, 172, 1092.	3.3	21
445	The Promise and the Reality of Genomics to Guide Precision Medicine in Pediatric Oncology: The Decade Ahead. Clinical Pharmacology and Therapeutics, 2020, 107, 176-180.	2.3	21
446	Childhood Acute Lymphoblastic Leukemia. Oncologist, 1997, 2, 374-380.	1.9	21
447	Gene Expression Profiles Distinguish Children Who Develop Therapy-Related Myeloid Leukemia.. Blood, 2004, 104, 397-397.	0.6	21
448	Interleukin-4 variant (BAY 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells. Blood, 2001, 97, 752-758.	0.6	20
449	Lack of benefit of early detection of relapse after completion of therapy for acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2005, 44, 138-141.	0.8	20
450	Expression of the outcome predictor in acute leukemia 1 (OPAL1) gene is not an independent prognostic factor in patients treated according to COALL or St Jude protocols. Blood, 2006, 108, 1984-1990.	0.6	20

#	Article	IF	Citations
451	T Cell Acute Lymphoblastic Leukemia: NOTCHing the Way toward a Better Treatment Outcome. Cancer Cell, 2009, 15, 85-87.	7.7	20
452	Association of Muscle Strength and Bone Mineral Density in Adult Survivors of Childhood Acute Lymphoblastic Leukemia. Archives of Physical Medicine and Rehabilitation, 2011, 92, 873-879.	0.5	20
453	Headache types, related morbidity, and quality of life in survivors of childhood acute lymphoblastic leukemia: A prospective cross sectional study. European Journal of Paediatric Neurology, 2014, 18, 722-729.	0.7	20
454	SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 439-446.	0.2	20
455	Predicting success of desensitization after pegaspargase allergy. Blood, 2020, 135, 71-75.	0.6	20
456	Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia. Journal of Clinical Investigation, 2021, 131, .	3.9	20
457	Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel. Transplantation and Cellular Therapy, 2022, 28, 73.e1-73.e9.	0.6	20
458	Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. Blood, 2022, 139, 3519-3531.	0.6	20
459	Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL. Blood Advances, 2022, 6, 5737-5749.	2.5	20
460	Adverse prognostic features in 251 children treated for acute myeloid leukemia. Medical and Pediatric Oncology, 1993, 21, 1-7.	1.0	19
461	Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies. Leukemia Research, 2004, 28, 349-352.	0.4	19
462	Treatment of acute lymphoblastic leukemia in low- and middle-income countries: Challenges and opportunities. Leukemia and Lymphoma, 2008, 49, 373-376.	0.6	19
463	Toward a Total Cure for Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2009, 27, 5121-5123.	0.8	19
464	Deficient innate immunity, thymopoiesis, and gene expression response to radiation in survivors of childhood acute lymphoblastic leukemia. Cancer Epidemiology, 2010, 34, 303-308.	0.8	19
465	Emotional distress in parents of long-term survivors of childhood acute lymphoblastic leukemia. Psycho-Oncology, 2015, 24, 1116-1123.	1.0	19
466	Clinical impact of sedentary behaviors in adult survivors of acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort study. Cancer, 2018, 124, 1036-1043.	2.0	19
467	The Impact of Persistent Leukoencephalopathy on Brain White Matter Microstructure in Long-Term Survivors of Acute Lymphoblastic Leukemia Treated with Chemotherapy Only. American Journal of Neuroradiology, 2018, 39, 1919-1925.	1.2	19
468	Neuroanatomical abnormalities related to dexamethasone exposure in survivors of childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e27968.	0.8	19

#	Article	IF	Citations
469	Treatment of Testicular Relapse of B-cell Acute Lymphoblastic Leukemia With CD19-specific Chimeric Antigen Receptor T Cells. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 366-370.	0.2	19
470	Early results of intensified remission induction chemotherapy for childhood acute lymphocytic leukemia. Medical and Pediatric Oncology, 1986, 14, 177-181.	1.0	18
471	Improving the segmentation of therapy-induced leukoencephalopathy in children with acute lymphoblastic leukemia using a priori information and a gradient magnitude threshold. Magnetic Resonance in Medicine, 2004, 52, 1336-1341.	1.9	18
472	BK Virus-Induced Tubulointerstitial Nephritis in a Child with Acute Lymphoblastic Leukemia. Journal of Pediatrics, 2007, 151, 215-217.	0.9	18
473	Symptoms of attentionâ€deficit/hyperactivity disorder in longâ€term survivors of childhood leukemia. Pediatric Blood and Cancer, 2011, 57, 1191-1196.	0.8	18
474	Prospective Randomized Crossover Evaluation of Three Anesthetic Regimens for Painful Procedures in Children with Cancer. Journal of Pediatrics, 2013, 162, 137-141.	0.9	18
475	Progress Born From a Legacy of Collaboration. Journal of Clinical Oncology, 2015, 33, 2935-2937.	0.8	18
476	Neurocognitive outcomes among children who experienced seizures during treatment for acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2017, 64, e26436.	0.8	18
477	Testicular involvement of acute lymphoblastic leukemia in children and adolescents: Diagnosis, biology, and management. Cancer, 2021, 127, 3067-3081.	2.0	18
478	Molecular diagnostics in the treatment of leukemia. Current Opinion in Hematology, 1999, 6, 229.	1.2	18
479	Pharmacogenomics of intracellular methotrexate polyglutamates in patientsâ€™ leukemia cells in vivo. Journal of Clinical Investigation, 2020, 130, 6600-6615.	3.9	18
480	Pitfalls in predicting tumor lysis syndrome. Leukemia and Lymphoma, 2006, 47, 782-785.	0.6	17
481	Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. Journal of Pediatric Hematology/Oncology, 2016, 38, 449-452.	0.3	17
482	Genetics of pleiotropic effects of dexamethasone. Pharmacogenetics and Genomics, 2017, 27, 294-302.	0.7	17
483	Diabetes mellitus among adult survivors of childhood acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort Study. Cancer, 2020, 126, 870-878.	2.0	17
484	Overt testicular disease at diagnosis is associated with high risk features and a poor prognosis in patients with childhood acute lymphoblastic leukemia. , 1996, 78, 2437-2442.		16
485	Does pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia: What can we learn from small studies?. Leukemia Research, 1997, 21, 435-437.	0.4	16
486	Toward optimal use of intrathecal liposomal cytarabine. Leukemia and Lymphoma, 2007, 48, 1672-1673.	0.6	16

#	Article	IF	Citations
487	Pulmonary alveolar proteinosis in pediatric leukemia. Pediatric Blood and Cancer, 2008, 51, 66-70.	0.8	16
488	Conservative Management of Pancreatic Pseudocysts in Children With Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2009, 31, 957-959.	0.3	16
489	Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies. British Journal of Haematology, 2012, 156, 275-279.	1.2	16
490	Bone turnover in longâ€term survivors of childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2014, 61, 1451-1456.	0.8	16
491	Genome-wide single-nucleotide polymorphism analysis revealed SUFU suppression of acute graft-versus-host disease through downregulation of HLA-DR expression in recipient dendritic cells. Scientific Reports, 2015, 5, 11098.	1.6	16
492	Effect of Premedications in a Murine Model of Asparaginase Hypersensitivity. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 541-551.	1.3	16
493	Association ofGATA3Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. Journal of the National Cancer Institute, 2021, 113, 408-417.	3.0	16
494	Prospective Analysis of TEL and MLL Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Childrenâ€™s Oncology Group Study.. Blood, 2006, 108, 218-218.	0.6	16
495	HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy. Clinical Chemistry, 2002, 48, 61-8.	1.5	16
496	Response of recurrent acute lymphoblastic leukemia to glucocorticoids: Serial studies of receptor content, in vivo cytokinetic changes and clinical responses. Leukemia Research, 1983, 7, 747-753.	0.4	15
497	Clinical Significance of Histology and Immunophenotype in Childhood Diffuse Large Cell Lymphoma. American Journal of Clinical Pathology, 1991, 95, 787-793.	0.4	15
498	Factor V Leiden and other hypercoagulable state mutations are not associated with osteonecrosis during or after treatment for pediatric malignancy. Journal of Pediatrics, 1999, 134, 310-314.	0.9	15
499	Global gene expression as a function of germline genetic variation. Human Molecular Genetics, 2005, 14, 1621-1629.	1.4	15
500	Intrathecal liposomal cytarabine: More friend than foe?. Leukemia and Lymphoma, 2008, 49, 1427-1430.	0.6	15
501	Incidental detection of late subsequent intracranial neoplasms with magnetic resonance imaging among adult survivors of childhood cancer. Journal of Cancer Survivorship, 2014, 8, 329-335.	1.5	15
502	Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks. Leukemia, 2021, 35, 3078-3091.	3.3	15
503	Individual-specific functional epigenomics reveals genetic determinants of adverse metabolic effects of glucocorticoids. Cell Metabolism, 2021, 33, 1592-1609.e7.	7.2	15
504	Urolithiasis in Childhood Acute Leukemia and Nonhodgkinâ€™s Lymphoma. Journal of Urology, 1986, 136, 1052-1054.	0.2	14

#	Article	IF	Citations
505	Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance. Clinical Pharmacology and Therapeutics, 1986, 39, 592-597.	2.3	14
506	Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia. Clinical Pharmacology and Therapeutics, 2003, 73, 506-516.	2.3	14
507	Statement by members of the Ponte di Legno Group on the right of children to have full access to essential treatment for acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2004, 43, 103-104.	0.8	14
508	Clofarabine. Nature Reviews Drug Discovery, 2005, 4, S12-S13.	21.5	14
509	How to solve the problem of hypersensitivity to asparaginase?. Pediatric Blood and Cancer, 2018, 65, e26884.	0.8	14
510	Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies. Clinical Cancer Research, 2019, 25, 7320-7330.	3.2	14
511	Identifying Priorities for Harmonizing Guidelines for the Long-Term Surveillance of Childhood Cancer Survivors in the Chinese Children Cancer Group (CCCG). JCO Global Oncology, 2021, 7, 261-276.	0.8	14
512	Prevalence and Growth Characteristics of Malignant Stem Cells in B-Lineage Acute Lymphoblastic Leukemia. Blood, 1997, 89, 3735-3744.	0.6	14
513	Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood, 2000, 96, 2691-2696.	0.6	14
514	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. Blood, 2018, 132, 565-565.	0.6	14
515	The frequency of illegitimate V(D)J recombinase-mediated mutations in children treated with etoposide-containing antileukemic therapy. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 1998, 419, 107-121.	0.9	13
516	Myositis complicating viridans streptococcal sepsis in childhood leukemia. Pediatric Blood and Cancer, 2005, 44, 277-279.	0.8	13
517	Randomized trial of 2 dosages of prophylactic granulocyteâ€“colonyâ€stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia. Cancer, 2011, 117, 1313-1320.	2.0	13
518	Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia. Therapeutic Advances in Hematology, 2020, 11, 204062072092757.	1.1	13
519	Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood, 2000, 96, 3381-3384.	0.6	13
520	Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia. PLoS ONE, 2015, 10, e0135134.	1.1	13
521	Methotrexate plus L-asparaginase. An active combination for children with acute nonlymphocytic leukemia. Cancer, 1990, 65, 2615-2618.	2.0	12
522	DISSEMINATED HISTOPLASMOSIS PRESENTING AS A CYSTIC DUCT OBSTRUCTION. Pediatric Infectious Disease Journal, 1992, 11, 593.	1.1	12

#	Article	IF	Citations
523	Bone marrow necrosis and thrombotic complications in childhood acute lymphoblastic leukemia. Medical and Pediatric Oncology, 1992, 20, 58-60.	1.0	12
524	Definition of cure in childhood acute myeloid leukemia. Cancer, 2014, 120, 2490-2496.	2.0	12
525	Dietary Protein Intake and Lean Muscle Mass in Survivors of Childhood Acute Lymphoblastic Leukemia: Report From the St. Jude Lifetime Cohort Study. Physical Therapy, 2016, 96, 1029-1038.	1.1	12
526	Association between dehydroepiandrosterone-sulfate and attention in long-term survivors of childhood acute lymphoblastic leukemia treated with only chemotherapy. Psychoneuroendocrinology, 2017, 76, 114-118.	1.3	12
527	Hypertension is a modifiable risk factor for osteonecrosis in acute lymphoblastic leukemia. Blood, 2019, 134, 983-986.	0.6	12
528	Treatment response and outcome of children with T-cell acute lymphoblastic leukemia expressing the gamma-delta T-cell receptor. OncoImmunology, 2019, 8, 1599637.	2.1	12
529	Neutropenia at the time of subcutaneous port insertion may not be a risk factor for early infectious complications in pediatric oncology patients. Journal of Pediatric Surgery, 2019, 54, 145-149.	0.8	12
530	Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia. Cancer, 2020, 126, 4800-4805.	2.0	12
531	Prospective randomized trial of interventions for vincristineâ€related neuropathic pain. Pediatric Blood and Cancer, 2020, 67, e28539.	0.8	12
532	Identification of small molecules that mitigate vincristineâ€induced neurotoxicity while sensitizing leukemia cells to vincristine. Clinical and Translational Science, 2021, 14, 1490-1504.	1.5	12
533	Chronic myeloproliferative disorders. , 0, , 571-598.		12
534	Glucocorticoid receptors in childhood acute non-lymphocytic leukemia. Leukemia Research, 1983, 7, 11-16.	0.4	11
535	Secondary leukaemias after epipodophyllotoxins. Lancet, The, 1992, 340, 672-673.	6.3	11
536	Cytogenetics as a Diagnostic Aid for Childhood Hematologic Disorders: Conventional Cytogenetic Techniques, Fluorescence In Situ Hybridization, and Comparative Genomic Hybridization. , 1998, , 209-228.		11
537	Computer-aided detection of therapy-induced leukoencephalopathy in pediatric acute lymphoblastic leukemia patients treated with intravenous high-dose methotrexate. Magnetic Resonance Imaging, 2006, 24, 785-791.	1.0	11
538	A subtle t(3;8) results in plausible juxtaposition of MYC and BCL6 in a child with Burkitt lymphoma/leukemia and ataxia-telangiectasia. Cancer Genetics and Cytogenetics, 2006, 168, 69-72.	1.0	11
539	Integrated analysis of pharmacologic, clinical and SNP microarray data using Projection Onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing. International Journal of Data Mining and Bioinformatics, 2011, 5, 143.	0.1	11
540	Palmarâ€plantar erythrodysesthesia syndrome following treatment with highâ€dose methotrexate or highâ€dose cytarabine. Cancer, 2017, 123, 3602-3608.	2.0	11

#	Article	IF	Citations
541	Serum Alanine Aminotransferase Elevations in Survivors of Childhood Cancer: A Report From the St. Jude Lifetime Cohort Study. Hepatology, 2019, 69, 94-106.	3.6	11
542	Bloodstream infections exacerbate incidence and severity of symptomatic glucocorticoidâ€induced osteonecrosis. Pediatric Blood and Cancer, 2019, 66, e27669.	0.8	11
543	Acute Lymphoblastic Leukemia. , 2011, , 23-26.		11
544	Primary hypothyroidism in childhood cancer survivors: Prevalence, risk factors, and longâ€term consequences. Cancer, 2022, 128, 606-614.	2.0	11
545	Recent advances in acute lymphoblastic leukemia. Oncology, 2011, 25, 341, 346-7.	0.4	11
546	Non-Hodgkin's lymphoma in children younger than 3 years. Cancer, 1988, 62, 1371-1373.	2.0	10
547	Therapy-related myeloid leukaemia. Lancet, The, 1990, 336, 1130-1131.	6.3	10
548	Clinical implications of cytogenetic and molecular analyses of pediatric acute lymphoblastic leukemia. Stem Cells, 1993, 11, 81-87.	1.4	10
549	Childhood acute lymphoblastic leukemia with equivocal chromosome markers of the t(I;I9) translocation. Genes Chromosomes and Cancer, 1995, 13, 99-103.	1.5	10
550	Is mega dose of methotrexate beneficial to patients with acute lymphoblastic leukemia?. Leukemia and Lymphoma, 2006, 47, 2431-2432.	0.6	10
551	The Health Utilities Index 3 Invalidated When Completed by Nurses for Pediatric Oncology Patients. Cancer Nursing, 2007, 30, 169-177.	0.7	10
552	Baseline mannose binding lectin levels may not predict infection among children with leukemia. Pediatric Blood and Cancer, 2008, 50, 866-868.	0.8	10
553	Spinal epidural lipomatosis in children with hematologic malignancies. Annals of Hematology, 2011, 90, 1067-1074.	0.8	10
554	Long-Term Outcome and Risk Factors for Uncontrolled Seizures After a First Seizure in Children With Hematological Malignancies. Journal of Child Neurology, 2014, 29, 774-781.	0.7	10
555	Growth hormone deficiency and neurocognitive function in adult survivors of childhood acute lymphoblastic leukemia. Cancer, 2019, 125, 1748-1755.	2.0	10
556	Longitudinal Trajectories of Neurocognitive Functioning in Childhood Acute Lymphoblastic Leukemia. Journal of Pediatric Psychology, 2021, 46, 168-178.	1.1	10
557	Antibiotic prophylaxis and the gastrointestinal resistome in paediatric patients with acute lymphoblastic leukaemia: a cohort study with metagenomic sequencing analysis. Lancet Microbe, The, 2021, 2, e159-e167.	3.4	10
558	Molecular Mechanisms of ARID5B-Mediated Genetic Susceptibility to Acute Lymphoblastic Leukemia. Journal of the National Cancer Institute, 2022, 114, 1287-1295.	3.0	10

#	Article	IF	Citations
559	Phagocytic activity and expression of myeloid-associated cell surface antigens by blast cells in acute lymphoblastic leukemia. Medical and Pediatric Oncology, 1986, 14, 12-16.	1.0	9
560	Nuclear translocation of lymphoblast glucocorticoid receptors in childhood leukemia does not predict steroid responsiveness. The Journal of Steroid Biochemistry, 1987, 26, 15-18.	1.3	9
561	Utility of automated counting to determine absolute neutrophil counts and absolute phagocyte counts for pediatric cancer treatment protocols. Cancer, 2004, 101, 2681-2686.	2.0	9
562	Epidemiology and etiology. , 0, , 48-66.		9
563	Cytogenetics of acute leukemias. , 0, , 235-271.		9
564	SVSI: Fast and Powerful Setâ€Valued System Identification Approach to Identifying Rare Variants in Sequencing Studies for Ordered Categorical Traits. Annals of Human Genetics, 2015, 79, 294-309.	0.3	9
565	Influence of fitness on health status among survivors of acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2018, 65, e27286.	0.8	9
566	International Collaboration to Save Children With Acute Lymphoblastic Leukemia. Journal of Global Oncology, 2019, 5, 1-2.	0.5	9
567	Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies. Pharmacogenomics Journal, 2019, 19, 305-314.	0.9	9
568	Genome-Wide Association Study of Susceptibility Loci for TCF3-PBX1 Acute Lymphoblastic Leukemia in Children. Journal of the National Cancer Institute, 2021, 113, 933-937.	3.0	9
569	Cardiac autonomic dysfunction in survivors of childhood acute lymphoblastic leukemia: The St. Jude Lifetime Cohort Study. Pediatric Blood and Cancer, 2020, 67, e28388.	0.8	9
570	Incidence of hip and knee osteonecrosis and their associations with bone mineral density in children with acute lymphoblastic leukaemia. British Journal of Haematology, 2020, 189, e177-e181.	1.2	9
571	Connectivity of the Cerebello-Thalamo-Cortical Pathway in Survivors of Childhood Leukemia Treated With Chemotherapy Only. JAMA Network Open, 2020, 3, e2025839.	2.8	9
572	Incidence of Germline Mutations in Cancer-Predisposition Genes in Children with Hematologic Malignancies: a Report from the Pediatric Cancer Genome Project. Blood, 2014, 124, 127-127.	0.6	9
573	Concordant Gene Expression in Leukemia Cells and Normal Leukocytes Is Associated with Germline cis-SNPs. PLoS ONE, 2008, 3, e2144.	1.1	8
574	Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia. Cancer, 2010, 116, 227-232.	2.0	8
575	Prophylactic cranial irradiation: going, going, gone. Lancet Oncology, The, 2009, 10, 932-933.	5.1	8
576	Epigenetic Regulation of Human Î³-Glutamyl Hydrolase Activity in Acute Lymphoblastic Leukemia Cells. American Journal of Human Genetics, 2010, 87, 161.	2.6	8

#	Article	IF	Citations
577	Successful treatment of pediatric plasmacytoid dendritic cell tumors with a contemporary regimen for acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2013, 60, E38-41.	0.8	8
578	No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. Pediatric Blood and Cancer, 2019, 66, e27681.	0.8	8
579	Cerebral microbleeds in adult survivors of childhood acute lymphoblastic leukemia treated with cranial radiation. Scientific Reports, 2020, 10, 692.	1.6	8
580	Genetic Abnormalities and Drug Resistance in Acute Lymphoblastic Leukemia. Advances in Experimental Medicine and Biology, 1999, 457, 383-389.	0.8	8
581	Risk Assessment in Acute Lymphoblastic Leukemia: Beyond Leukemia Cell Characteristics. The American Journal of Pediatric Hematology/oncology, 2001, 23, 405-408.	1.3	8
582	Acute Lymphoblastic Leukemia in Children with Down Syndrome: A Report From the Ponte Di Legno Study Group,. Blood, 2011, 118, 3579-3579.	0.6	8
583	Genomic Characterization and Experimental Modeling Of BCR-ABL1-Like Acute Lymphoblastic Leukemia. Blood, 2013, 122, 232-232.	0.6	8
584	Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome. Blood, 2013, 122, 825-825.	0.6	8
585	Higher Frequency of Glutathione S-Transferase Deletions in Black Children With Acute Lymphoblastic Leukemia. Blood, 1997, 89, 1701-1707.	0.6	8
586	A Whole Genome Analysis Identifies SLCO1B1 as a Determinant of Methotrexate Pharmacokinetics and Adverse Effects. Blood, 2008, 112, 214-214.	0.6	8
587	Recent advances in childhood acute lymphoblastic leukemia. Journal of the Formosan Medical Association, 2004, 103, 85-95.	0.8	8
588	Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia. Blood Advances, 2022, 6, 3386-3397.	2.5	8
589	Hydrocele formation in patients with Hodgkin's disease. Cancer, 1983, 51, 2301-2303.	2.0	7
590	Testicular relapse in children with acute nonlymphoblastic leukemia. Cancer, 1990, 66, 2095-2098.	2.0	7
591	Can the genotoxicity of chemotherapy be predicted?. Lancet, The, 2004, 364, 917-918.	6.3	7
592	Acute lymphoblastic leukemia. , 0, , 439-472.		7
593	Combination of dexamethasone, highâ€dose cytarabine, and carboplatin is effective for advanced largeâ€cell nonâ€Hodgkin lymphoma of childhood. Cancer, 2008, 113, 782-790.	2.0	7
594	Healthcare-Associated Infections at a Children's Cancer Hospital, 1983â€“2008. Journal of the Pediatric Infectious Diseases Society, 2012, 1, 26-34.	0.6	7

#	Article	IF	Citations
595	Is testicular irradiation necessary for patients with acute lymphoblastic leukemia and testicular relapse?. Pediatric Blood and Cancer, 2018, 65, e26977.	0.8	7
596	Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia. Cancer Medicine, 2020, 9, 6550-6555.	1.3	7
597	Ultrasound has limited diagnostic utility in children with acute lymphoblastic leukemia developing pancreatitis. Pediatric Blood and Cancer, 2021, 68, e28730.	0.8	7
598	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. Clinical Pharmacology and Therapeutics, 2021, 110, 794-802.	2.3	7
599	Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia. Pharmacogenetics and Genomics, 2022, 32, 60-66.	0.7	7
600	Phase I Clinical Trial of the Anti-CD22 Immunotoxin CAT-8015 (HA22) for Pediatric Acute Lymphoblastic Leukemia (ALL).. Blood, 2009, 114, 839-839.	0.6	7
601	Transcriptome Sequence Analysis of Pediatric Acute Megakaryoblastic Leukemia Identifies An Inv(16)(p13.3;q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein As a Recurrent Lesion in 39% of Non-Infant Cases: A Report From the St. Jude Children's Research Hospital â€“ Washington University Pediatric Cancer Genome Project. Blood, 2011, 118, 757-757.	0.6	7
602	Hyperuricemia in Patients with Cancer. American Journal of Cancer, 2002, 1, 409-422.	0.4	6
603	The relationship of child executive functions to parenting capacities in childhood acute lymphoblastic leukemia survivors. Pediatric Blood and Cancer, 2019, 66, e27761.	0.8	6
604	FPGS relapse-specific mutations in relapsed childhood acute lymphoblastic leukemia. Scientific Reports, 2020, 10, 12074.	1.6	6
605	Wholeâ€joint magnetic resonance imaging to assess osteonecrosis in pediatric patients with acute lymphoblastic lymphoma. Pediatric Blood and Cancer, 2020, 67, e28336.	0.8	6
606	Whole Genome Sequence Analysis of 22 MLL Rearranged Infant Acute Lymphoblastic Leukemias Reveals Remarkably Few Somatic Mutations: A Report From the St Jude Childrenâ€˜s Research Hospital - Washington University Pediatric Cancer Genome Project. Blood, 2011, 118, 69-69.	0.6	6
607	Genome-Wide Association Analyses Identify Susceptibility Loci For Vincristine-Induced Peripheral Neuropathy In Children With Acute Lymphoblastic Leukemia. Blood, 2013, 122, 618-618.	0.6	6
608	Early Intensification of Intrathecal Chemotherapy Virtually Eliminates Central Nervous System Relapse in Children With Acute Lymphoblastic Leukemia. Blood, 1998, 92, 411-415.	0.6	6
609	Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy. Blood, 2014, 124, 63-63.	0.6	6
610	ACUTE LEUKAEMIA WITH MIXED LYMPHOID AND MYELOID PHENOTYPE. British Journal of Haematology, 1984, 58, 203-205.	1.2	5
611	Clinical and biologic correlates of insulin binding by leukemia lymphoblasts. Leukemia Research, 1985, 9, 843-849.	0.4	5
612	Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia: Real Improvement With the Real-Time Quantitative PCR Method?. Journal of Pediatric Hematology/Oncology, 2003, 25, 100-102.	0.3	5

#	Article	IF	Citations
613	Acute complications. , 2006, , 709-749.		5
614	Diagnosis and classification. , 0, , 21-47.		5
615	Reducing delayed intensification therapy in childhood ALL. Lancet Oncology, The, 2013, 14, 178-179.	5.1	5
616	Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia. , 2013, , 305-329.		5
617	Tumor Lysis Syndrome. , 2014, , 39-64.		5
618	Higher plasma asparaginase activity after intramuscular than intravenous Erwinia asparaginase. Pediatric Blood and Cancer, 2020, 67, e28244.	0.8	5
619	Effects of NT5C2 Germline Variants on 6â€Mecaptopurine Metabolism in Children With Acute Lymphoblastic Leukemia. Clinical Pharmacology and Therapeutics, 2021, 109, 1538-1545.	2.3	5
620	Clinicopathologic and prognostic features of TdT-negative pediatric B-lymphoblastic leukemia. Modern Pathology, 2021, 34, 2050-2054.	2.9	5
621	Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase. Cancer Chemotherapy and Pharmacology, 2021, 88, 655-664.	1.1	5
622	Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy. Haematologica, 2022, 107, 371-380.	1.7	5
623	Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia. JAMA Oncology, 2021, 7, 1521-1528.	3.4	5
624	Defining the Optimal Dosage of Methotrexate for Childhood Acute Lymphoblastic Leukemia. Advances in Experimental Medicine and Biology, 1999, 457, 537-541.	0.8	5
625	Childhood Leukemia. , 2014, , 1849-1872.e11.		5
626	Acute Lymphocytic Leukemia in Childhood. Southern Medical Journal, 1987, 80, 841-847.	0.3	5
627	Improved Remission Induction Rate of Childhood AML: Preliminary Results of the AML02 Trial.. Blood, 2005, 106, 275-275.	0.6	5
628	A Genome-Wide Analysis of Variants Influencing Methotrexate Clearance Replicates SLCO1B1.. Blood, 2012, 120, 2466-2466.	0.6	5
629	Minimal residual disease in pediatric ALL. Oncotarget, 2017, 8, 78251-78252.	0.8	5
630	Identification of Gene Expression Profiles in Acute Lymphoblastic Leukemia Cells That Discriminate Intracellular Thioguanine Nucleotide Accumulation in ALL Cells after In Vivo Treatment with Mercaptopurine.. Blood, 2004, 104, 453-453.	0.6	5

#	Article	IF	Citations
631	Current Approaches to Therapy for Childhood Lymphoblastic Leukemia: St. Jude Studies XI (1984â€“1988) and XII (1988). Hamatologie Und Bluttransfusion, 1989, 32, 58-64.	0.0	5
632	The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia. Blood, 2019, 134, 649-649.	0.6	5
633	Pre-B-Cell Acute Lymphoblastic Leukemia in Childhood. Leukemia and Lymphoma, 1990, 3, 1-6.	0.6	4
634	Quest for effective agents to combat T-cell acute lymphoblastic leukemia. European Journal of Cancer, 2005, 41, 1243-1245.	1.3	4
635	Anatomy and physiology of hematopoiesis. , 0, , 69-105.		4
636	Prognostic significance of myeloperoxidase expression in childhood acute myeloid leukemia. Pediatric Blood and Cancer, 2008, 50, 542-548.	0.8	4
637	Components of cure: Treatment of acute lymphoblastic leukemia in Indonesia and other lowâ€income countries. Pediatric Blood and Cancer, 2008, 51, 719-721.	0.8	4
638	Are children with lesser-risk B-lineage acute lymphoblastic leukemia curable with antimetabolite therapy?. Nature Clinical Practice Oncology, 2008, 5, 130-131.	4.3	4
639	Redefining â€œrareâ€•in paediatric cancers. Lancet Oncology, The, 2016, 17, 138-139.	5.1	4
640	A p53-regulated apoptotic gene signature predicts treatment response and outcome in pediatric acute lymphoblastic leukemia. Cancer Management and Research, 2017, Volume 9, 397-410.	0.9	4
641	Association between obesity and neurocognitive function in survivors of childhood acute lymphoblastic leukemia treated only with chemotherapy. Cancer, 2021, 127, 3202-3213.	2.0	4
642	Toward the Cure of Acute Lymphoblastic Leukemia in Children in China. JCO Global Oncology, 2021, 7, 1176-1186.	0.8	4
643	Neuropathic pain and neurocognitive functioning in children treated for acute lymphoblastic leukemia. Pain, 2022, 163, 1070-1077.	2.0	4
644	Pharmacodynamic Monitoring of Cancer Chemotherapy: Childhood Acute Lymphoblastic Leukemia as a Model. Therapeutic Drug Monitoring, 1998, 20, 453-458.	1.0	4
645	Abstract 4869: Whole genome sequence analysis of MLL rearranged infant acute lymphoblastic leukemias reveals remarkably few somatic mutations: A Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. , 2012, , .		4
646	Biological and therapeutic aspects of infant leukemia. Blood, 2000, 96, 24-33.	0.6	4
647	Impact of risk-stratified therapy on health status in survivors of childhood Acute Lymphoblastic Leukemia: a report from the Childhood Cancer Survivor Study. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0667.2021.	1.1	4
648	IKZF1 and 22q11.22 Deletions and PDGFRA Gains Are Associated with Poor Outcome in Down Syndrome Acute Lymphoblastic Leukemia. Blood, 2012, 120, 289-289.	0.6	4

#	Article	IF	Citations
649	Sex-Based Differences in Functional Brain Activity During Working Memory in Survivors of Pediatric Acute Lymphoblastic Leukemia. JNCI Cancer Spectrum, 2022, 6, .	1.4	4
650	Dasatinibâ€therapy induced sustained remission in a child with refractory TCF7â€SPI1 Tâ€cell acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2022, 69, e29724.	0.8	4
651	T-Cell Acute Lymphoblastic Leukemia with t(11;14) in Children. Leukemia and Lymphoma, 1992, 7, 351-358.	0.6	3
652	Impact of molecular profiling and cytogenetics in acute lymphoblastic leukemia. Hematology, 2005, 10, 176-177.	0.7	3
653	Immunophenotyping. , 2006, , 150-209.		3
654	Neonatal leukemia: A nemesis for pediatric oncologists?. Pediatric Blood and Cancer, 2006, 47, 234-235.	0.8	3
655	Diagnosis and classification. , 0, , 21-48.		3
656	Epidemiology and etiology. , 0, , 49-71.		3
657	History of leukemia: historical perspectives. , 0, , 1-20.		3
658	Is Erwinase Necessary for all Children With ALL and Allergic Reactions to E. coli Asparaginase?. Pediatric Blood and Cancer, 2016, 63, 587-588.	0.8	3
659	Dosing-related saturation of toxicity and accelerated drug clearance with pegaspargase treatment. Blood, 2020, 136, 2955-2958.	0.6	3
660	Management of pancreatic pseudocysts in pediatric oncology patients. Journal of Pediatric Surgery, 2020, 55, 1727-1731.	0.8	3
661	The International Collaboration to Save Children With Cancer. JAMA Oncology, 2021, 7, 499.	3.4	3
662	Why do subcutaneous ports get stuck? A case-control study. Journal of Pediatric Surgery, 2022, 57, 229-233.	0.8	3
663	Allogeneic Hematopoietic Cell Transplantation Is Critical to Maintain Remissions after CD19-CAR T-Cell Therapy for Pediatric ALL: A Single Center Experience. Blood, 2020, 136, 39-40.	0.6	3
664	Acute Megakaryoblastic Leukemia (AMKL) in Children without Down Syndrome.. Blood, 2009, 114, 482-482.	0.6	3
665	Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Sorafenib In Pediatric Acute Myeloid Leukemia.. Blood, 2010, 116, 1073-1073.	0.6	3
666	Complete Remissions In 3 of 12 Patients with Pediatric Acute Lymphoblastic Leukemia (ALL) During Phase I Testing of the Anti-CD22 Immunotoxin Moxetumomab Pasudotox. Blood, 2010, 116, 3246-3246.	0.6	3

#	Article	IF	Citations
667	Acute Appendicitis in Children with Leukemia: Unique Diagnostic Process, Management, and Outcome. Blood, 2015, 126, 4872-4872.	0.6	3
668	Parent-Reported and Self-Perceived Behavioral and Psychiatric Symptoms in Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia. Blood, 2016, 128, 3594-3594.	0.6	3
669	Germline Genetic Variation in IKZF1 and Predisposition to Childhood Acute Lymphoblastic Leukemia. Blood, 2016, 128, LBA-2-LBA-2.	0.6	3
670	Reduced Folate Carrier Expression in Acute Lymphoblastic Leukemia: A Mechanism for Ploidy but not Lineage Differences in Methotrexate Accumulation. Blood, 1999, 93, 1643-1650.	0.6	3
671	Functional consequence of cognitive impairment in survivors of childhood acute lymphoblastic leukemia (ALL): The role of cancer symptoms as mediators.. Journal of Clinical Oncology, 2016, 34, 235-235.	0.8	3
672	Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed or refractory acute myeloid leukemia.. Journal of Clinical Oncology, 2019, 37, 10004-10004.	0.8	3
673	Gene Expression Patterns Associated with Cytarabine Pharmacology and Outcome in Pediatric Acute Myeloid Leukemia.. Blood, 2009, 114, 114-114.	0.6	3
674	PDE4B Modulates Glucocorticoid Sensitivity in Childhood Acute Lymphoblastic Leukemia. Blood, 2012, 120, 530-530.	0.6	3
675	Genomic Landscape of Relapsed Acute Lymphoblastic Leukemia. Blood, 2015, 126, 692-692.	0.6	3
676	Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome. Blood Advances, 2022, 6, 2824-2834.	2.5	3
677	Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication. Clinical Cancer Research, 2022, 28, 2536-2546.	3.2	3
678	The walls of a spacious room. Medical and Pediatric Oncology, 2001, 36, 312-313.	1.0	2
679	Cure of childhood ALL: exacting a lower toll. Blood, 2002, 99, 4255-4256.	0.6	2
680	Relapsed acute lymphoblastic leukemia. , 0, , 473-486.		2
681	Immunoglobulin and T-cell receptor gene rearrangements. , 2006, , 210-234.		2
682	Acute myeloid leukemia. , 2006, , 499-539.		2
683	Two tales of infant leukemia. Blood, 2006, 107, 4576-4577.	0.6	2
684	Molecular genetics of acute lymphoblastic leukemia. , 0, , 168-203.		2

#	Article	IF	Citations
685	Molecular genetics of acute myeloid leukemia. , 0, , 204-238.		2
686	Acute lymphoblastic leukemia. , 0, , 332-366.		2
687	To delay or not to delay, that is the question for patients with acute lymphoblastic leukemia who do not receive prophylactic cranial irradiation. Cancer, 2018, 124, 4442-4446.	2.0	2
688	Clinical Manifestations and Treatment of Childhood Acute Lymphoblastic Leukemia. , 2018, , 1020-1028.		2
689	Integrative genomic analysis of Bâ€lymphoblastic lymphoma with intrachromosomal amplification of chromosome 21. Pediatric Blood and Cancer, 2020, 67, e28357.	0.8	2
690	Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies. Cancer, 2021, 127, 2074-2082.	2.0	2
691	Childhood Acute Lymphoblastic Leukaemia. , 0, , 542-560.		2
692	Acute Lymphoblastic Leukemia. , 2015, , 39-43.		2
693	Hematopoietic stem cell transplantation. , 0, , 599-624.		2
694	Pegaspargase Allergic Reactions Are Related to Anti-Pegaspargase Antibodies and to Intensity of Intrathecal Therapy. Blood, 2018, 132, 2697-2697.	0.6	2
695	Genome-Wide Association Study Identifies PNPLA3 I148M Variant Associated with Elevated Transaminase Levels after Induction Therapy in Pediatric ALL Patients. Blood, 2015, 126, 3714-3714.	0.6	2
696	Assessment of Central Nervous System Involvement in Pediatric Acute Lymphoblastic Leukemia Patients Using Next-Generation Sequencing Method. Blood, 2015, 126, 4981-4981.	0.6	2
697	Family environment, parent protection, and quality of life in childhood acute lymphoblastic leukemia (ALL) survivors.. Journal of Clinical Oncology, 2015, 33, e21027-e21027.	0.8	2
698	Syndrome of Inappropriate Secretion of Anti-Diuretic Hormone in Children with Acute Lymphoblastic Leukemia.. Blood, 2006, 108, 4474-4474.	0.6	2
699	Genome-Wide Association Study Identifies a Novel Susceptibility Locus At 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethinically Diverse Populations. Blood, 2012, 120, 877-877.	0.6	2
700	Cyclosporin A Induces Apoptosis in Childhood Acute Lymphoblastic Leukemia Cells. Blood, 1998, 91, 1001-1007.	0.6	2
701	High Incidence of Induction Failure and Poor Outcome in Patients with Gamma Delta T Cell Acute Lymphoblastic Leukemia. Blood, 2015, 126, 1421-1421.	0.6	2
702	Germline Genetic Variation in ETV6 and Predisposition to Childhood Acute Lymphoblastic Leukemia. Blood, 2015, 126, 695-695.	0.6	2

#	Article	IF	Citations
703	Heritable predispositions to childhood hematologic malignancies. , 0, , 362-388.		2
704	Update on Pediatric ALL. Clinical Advances in Hematology and Oncology, 2006, 4, 884-6.	0.3	2
705	Pediatric Cardio-Oncology Medicine: A New Approach in Cardiovascular Care. Children, 2021, 8, 1200.	0.6	2
706	Simultaneous monitoring of disease and microbe dynamics through plasma DNA sequencing in pediatric patients with acute lymphoblastic leukemia. Science Advances, 2022, 8, eabj1360.	4.7	2
707	Impact of T-cell immunity on chemotherapy response in childhood acute lymphoblastic leukemia. Blood, 2022, 140, 1507-1521.	0.6	2
708	Vitamin K-dependent coagulation proteins in asparaginase-induced thrombosis. Journal of Pediatrics, 1986, 109, 908-909.	0.9	1
709	A case of testicular fibrosis ultrasonographically mimicking leukemic infiltration after treatment for testicular relapse. Medical and Pediatric Oncology, 1995, 25, 123-125.	1.0	1
710	Acute Lymphoid Leukemia Outcomes in Black and White Children-Reply. JAMA - Journal of the American Medical Association, 1995, 274, 380.	3.8	1
711	Continue to study childhood ALL. Blood, 2008, 111, 468-469.	0.6	1
712	Integrated Analysis of Pharmacokinetic, Clinical, and SNP Microarray Data Using Projection onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing. , 2009, , .		1
713	Immunophenotyping. , 0, , 72-112.		1
714	Cytogenetics of acute leukemias. , 0, , 135-167.		1
715	Genetics and cellular drug resistance in acute leukemia. , 2012, , 257-275.		1
716	B-cell acute lymphoblastic leukemia and Burkitt lymphoma. , 0, , 383-394.		1
717	Acute myeloid leukemia. , 0, , 395-420.		1
718	Leukemias in patients with Down syndrome. , 0, , 503-519.		1
719	Acute complications. , 0, , 660-700.		1
720	Therapy-related leukemias. , 0, , 723-771.		1

#	Article	IF	Citations
721	Psychosocial issues. , 2012, , 823-838.		1
722	Relapsed acute lymphoblastic leukemia. , 2012, , 367-382.		1
723	Osteonecrosis is unrelated to hip anatomy in children with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2017, 64, e26407.	0.8	1
724	Evaluation of Chest Radiographs of Children with Newly Diagnosed AcuteÂLymphoblastic Leukemia. Journal of Pediatrics, 2020, 223, 120-127.e3.	0.9	1
725	Therapy-induced mutagenesis in relapsed ALL is supported by mutational signature analysis. Blood, 2020, 136, 2235-2237.	0.6	1
726	Leukemias. , 1998, , 233-239.		1
727	B-cell acute lymphoblastic leukemia and Burkitt lymphoma. , 2006, , 487-498.		1
728	Myelodysplastic syndrome. , 0, , 548-570.		1
729	Minimal residual disease. , 2006, , 679-706.		1
730	Therapy-related leukemias. , 2006, , 774-804.		1
731	Abstract 2033: Germline mutations inETV6confer risk of thrombocytopenia and acute lymphocytic leukemia. , 2015, , .		1
732	Abstract 4369: Rearrangements of the erythropoietin receptor are recurrent in Ph-like acute lymphoblastic leukemia and are sensitive to Jak2 inhibition. , 2015, , .		1
733	Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Determinants of Osteonecrosis In Children with Acute Lymphoblastic Leukemia.. Blood, 2010, 116, 1033-1033.	0.6	1
734	HLA-DRB1*07:01 Is Associated With Asparaginase Allergies In Children With Acute Lymphoblastic Leukemia. Blood, 2013, 122, 60-60.	0.6	1
735	Glutamate Receptor Polymorphisms Contribute to Glucocorticoid-Associated Osteonecrosis. Blood, 2014, 124, 367-367.	0.6	1
736	Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia. Blood, 2015, 126, 693-693.	0.6	1
737	Comprehensive Functional Characterization of Germline ETV6 Variants Associated with Inherited Predisposition to Acute Lymphoblastic Leukemia in Children. Blood, 2016, 128, 1085-1085.	0.6	1
738	a Phase I Trial of Bendamustine in Combination with Clofarabine and Etoposide in Pediatric Patients with Relapsed or Refractory Hematologic Malignancies. Blood, 2016, 128, 1628-1628.	0.6	1

#	Article	IF	Citations
739	Hyperdiploid Acute Lymphoblastic Leukemia With 51 to 65 Chromosomes: A Distinct Biological Entity With a Marked Propensity to Undergo Apoptosis. Blood, 1999, 93, 315-320.	0.6	1
740	Subcortical brain volumes and neurocognitive function in survivors of childhood acute lymphoblastic leukemia (ALL) treated with chemotherapy-only.. Journal of Clinical Oncology, 2017, 35, 10517-10517.	0.8	1
741	Genes Regulating B-Cell Development and Differentiation Are Mutated in 40% of Pediatric Acute Lymphoblastic Leukemia.. Blood, 2006, 108, 217-217.	0.6	1
742	Childhood Leukemia. , 2008, , 2139-2169.		1
743	Genetically Defined Racial Differences Underlie Risk of Relapse in Childhood Acute Lymphoblastic Leukemia. Blood, 2008, 112, 14-14.	0.6	1
744	CREBBP Mutations In Relapsed Acute Lymphoblastic Leukemia. Blood, 2010, 116, 413-413.	0.6	1
745	Excellent Outcome for ETV6/RUNX1-Positive Childhood Acute Lymphoblastic Leukemia (ALL) with Contemporary Therapy. Blood, 2010, 116, 495-495.	0.6	1
746	Clinical Utility and Implications of Asparaginase Antibodies in Acute Lymphoblastic Leukemia. Blood, 2011, 118, 1481-1481.	0.6	1
747	Abstract 4870: Integrated genomic analysis of hypodiploid acute lymphoblastic leukemia. , 2012, , .		1
748	Long-Term Memory Deficits and Early Onset Dementia in Aging Adult Survivors of Childhood Acute Lymphoblastic Leukemia Treated with Cranial Irradiation. Blood, 2012, 120, 664-664.	0.6	1
749	A Genome-Wide Association Study of Susceptibility to Acute Lymphoblastic Leukemia in Adolescents and Young Adults. Blood, 2014, 124, 132-132.	0.6	1
750	Assessment of Central Nervous System Involvement in Pediatric Acute Lymphoblastic Leukemia Patients Using Next-Generation Sequencing Method. Blood, 2014, 124, 5343-5343.	0.6	1
751	Antileukemic Efficacy of Continuous Vs Discontinuous Dexamethasone in Murine Xenografts of Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3701-3701.	0.6	1
752	Acute Lymphoblastic Leukemia. , 2015, , 1-5.		1
753	Pulmonary function in adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort Study (SJLIFE).. Journal of Clinical Oncology, 2015, 33, 10018-10018.	0.8	1
754	Cognitive, Behavior and Academic Problems in Adolescent Survivors of Childhood Acute Lymphoblastic Leukemia (ALL): A Report from the Childhood Cancer Survivor Study. Blood, 2015, 126, 877-877.	0.6	1
755	Association Between Acute Leukoencephalopathy and Long-Term Neurobehavioral and Brain Imaging Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia Treated with Chemotherapy Only. Blood, 2015, 126, 3255-3255.	0.6	1
756	Pharmacokinetic, pharmacodynamic, and pharmacogenetic considerations. , 2006, , 391-413.		1

#	Article	IF	Citations
757	Hematologic supportive care. , 2006, , 829-849.		1
758	Clofarabine-Based Chemotherapy for KMT2Ar Infantile Acute Lymphoblastic Leukemia. Blood, 2021, 138, 3406-3406.	0.6	1
759	Current concepts in treatment of childhood acute lymphoblastic leukemia. International Journal of Hematology, 2002, 76, 279-279.	0.7	0
760	Genetics of childhood acute lymphoblastic leukemia. International Journal of Hematology, 2002, 76, 58-58.	0.7	0
761	Differentiating therapy-induced leukoencephalopathy from unmyelinated white matter in children treated for acute lymphoblastic leukemia (ALL). , 2003, , .		0
762	Improving the segmentation of therapy-induced leukoencephalopathy using apriori information and a gradient magnitude threshold. , 2004, 5370, 1738.		0
763	Quantitative MRI assessments of white matter in children treated for acute lymphoblastic leukemia. , 2005, 5746, 604.		0
764	Relapsed acute myeloid leukemia. , 2006, , 540-547.		0
765	Signal transduction in the regulation of hematopoiesis. , 0, , 125-149.		0
766	Molecular genetics of acute lymphoblastic leukemia. , 2006, , 272-297.		0
767	Apoptosis and chemoresistance. , 0, , 339-361.		0
768	Psychosocial issues. , 0, , 858-881.		0
769	Hematopoietic growth factors. , 2006, , 106-124.		0
770	Adoptive cellular immunotherapy. , 2006, , 648-660.		0
771	Gene transfer: methods and applications. , 2006, , 661-678.		0
772	Molecular genetics of acute myeloid leukemia. , 2006, , 298-338.		0
773	Livin: a proapoptotic factor in ALL?. Blood, 2007, 109, 394-395.	0.6	0
774	Response: Genes associated with response to therapy in childhood acute lymphoblastic leukemia. Blood, 2008, 111, 2487-2488.	0.6	0

#	Article	IF	Citations
775	Immunoglobulin and T-cell receptor gene rearrangements. , 0, , 113-134.		0
776	Epigenetics of leukemia. , 0, , 239-256.		0
777	Heritable predisposition to childhood hematologic malignancies. , 0, , 276-308.		0
778	Pharmacokinetic, pharmacodynamic, and pharmacogenetic considerations. , 0, , 309-331.		0
779	Relapsed acute myeloid leukemia. , 0, , 421-428.		0
780	Myelodysplastic syndrome. , 0, , 429-443.		0
781	Treatment of adolescents and young adults with acute lymphoblastic leukemia. , 0, , 520-526.		0
782	Hematopoietic stem cell and natural killer cell transplantation. , 0, , 527-548.		0
783	Treatment of acute leukemia in countries with limited resources. , 0, , 549-562.		0
784	Antibody-targeted therapy. , 0, , 563-581.		0
785	Development therapeutics. , 0, , 616-631.		0
786	Minimal residual disease. , 0, , 632-659.		0
787	Late complications after leukemia therapy. , 0, , 701-722.		0
788	Infectious complications in leukemia. , 0, , 772-793.		0
789	Hematologic supportive care. , 0, , 794-813.		0
790	Nursing care. , 0, , 839-850.		0
791	Germline exome variation in children with acute lymphoblastic leukemia (ALL): Preliminary Findings. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S177.	0.2	0
792	Characterization of new cryptic rearrangements of the erythropoietin receptor in Ph-like acute lymphoblastic leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S175-S176.	0.2	0

#	Article	IF	Citations
793	Is another antibody conjugate against ALL needed?. Lancet Haematology,the, 2015, 2, e87-e88.	2.2	0
794	Clinical manifestations of sepsis during nonfatal bacteremia in pediatric patients undergoing therapy for acute lymphoblastic leukemia. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
795	Reply to S. Kaur et al. Journal of Clinical Oncology, 2016, 34, 3708-3709.	0.8	0
796	Progress in the Study of Pediatric ALL. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S65-S67.	0.2	0
797	Derâ€Cherng Liang, MD, 1947â€“2017. Pediatric Blood and Cancer, 2018, 65, e26979.	0.8	0
798	Childhood Acute Lymphoblastic Leukemia: How to Cure the Very High Risk?. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S2-S5.	0.2	0
799	Association of Anesthesia Care and Cognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemiaâ€”Reply. JAMA Oncology, 2020, 6, 158.	3.4	0
800	Intensive but tender care for infant ALL. Blood, 2020, 136, 1797-1798.	0.6	0
801	Joseph V. Simone: In Memoriam (1935â€“2021). Clinical Cancer Research, 2021, 27, 1821-1822.	3.2	0
802	Activity of venetoclax against relapsed acute undifferentiated leukemia. Cancer, 2021, 127, 2608-2611.	2.0	0
803	Abstract 2118: Non-coding germline GATA3 variants alter chromatin topology and contribute to pathogenesis of acute lymphoblastic leukemia. , 2021, , .		0
804	Abstract 642: Genomes for Kids: Comprehensive DNA and RNA sequencing defining the scope of actionable mutations in pediatric cancer. , 2021, , .		0
805	Reduced intensity chemotherapy with tyrosine kinase inhibitor and blinatumomab in a pediatric patient with Philadelphia chromosomeâ€positive ALL and mechanical heart valves. Pediatric Blood and Cancer, 2021, 68, e28924.	0.8	0
806	Pharmacodynamics in Childhood Acute Lymphoblastic Leukemia. Hamatologie Und Bluttransfusion, 2001, , 364-369.	0.0	0
807	Racial Differences in Rates of Traumatic Lumbar Punctureâ€”Reply. JAMA - Journal of the American Medical Association, 2003, 289, 549.	3.8	0
808	Genetic Polymorphisms in the Promoter Region of the beta-2 Adrenergic Receptor Are Associated with the Early Response of Acute Lymphoblastic Leukemia to Chemotherapy.. Blood, 2004, 104, 1959-1959.	0.6	0
809	Genetic Polymorphisms and the Toxicity of Antileukemic Agents in Children with Acute Lymphoblastic Leukemia.. Blood, 2004, 104, 1964-1964.	0.6	0
810	Lymphoid malignancies in children. , 2004, , 482-499.		0

#	Article	IF	Citations
811	Outcome after Relapse of Childhood Acute Myeloid Leukemia: The St. Jude Experience.. Blood, 2005, 106, 273-273.	0.6	0
812	Genome Scan for Therapy-Related Leukemia.. Blood, 2005, 106, 3254-3254.	0.6	0
813	Inosine-Triphosphate-Pyrophosphatase Genotype Is a Determinant of Severe Fever with Neutropenia Following Treatment of Acute Lymphoblastic Leukemia with Combination Chemotherapy That Includes Mercaptopurine Adjusted for Thiopurine-S-Methyltransferase Genotype.. Blood, 2007, 110, 2827-2827.	0.6	0
814	Etoposide Sensitivity Does Not Predict MLL Rearrangements or Risk of Therapy-Related Acute Myeloid Leukemia.. Blood, 2007, 110, 1829-1829.	0.6	0
815	Genetic Variations in GRIA1 On Chromosome 5q33 Related to Asparaginase Hypersensitivity in Childhood Acute Lymphoblastic Leukemia (ALL).. Blood, 2009, 114, 112-112.	0.6	0
816	Rearrangement of CRLF2 in B-Progenitor and Down Syndrome Associated Acute Lymphoblastic Leukemia.. Blood, 2009, 114, 182-182.	0.6	0
817	Longitudinal Analysis of Antibody Response to Immunization in Pediatric Survivors After Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2009, 114, 795-795.	0.6	0
818	Minimal Residual Diseaseâ€“Directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial.. Blood, 2009, 114, 16-16.	0.6	0
819	Improved Prognosis for Older Adolescents with Acute Lymphoblastic Leukemia. Blood, 2010, 116, 498-498.	0.6	0
820	Longitudinal Analysis of Body Mass and Composition in Survivors of Pediatric Hematological Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2011, 118, 1991-1991.	0.6	0
821	SLCO1B1 Variation and Methotrexate Disposition in Children with Acute Lymphoblastic Leukemia: The Importance of Rare Variants in Pharmacogenetics. Blood, 2011, 118, 571-571.	0.6	0
822	Novel Chromosomal Rearrangements and Sequence Mutations in High-Risk Ph-Like Acute Lymphoblastic Leukemia. Blood, 2011, 118, 67-67.	0.6	0
823	Focal 22q11.22 Loss Combined with IKZF1 Alterations Predict Very Poor Outcome in Childhood Acute Lymphoblastic Leukemia. Blood, 2011, 118, 741-741.	0.6	0
824	Systemic Exposure to Dexamethasone and Asparaginase Affects Risk of Relapse in Children with Acute Lymphoblastic Leukemia. Blood, 2011, 118, 2550-2550.	0.6	0
825	Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. Blood, 2011, 118, 68-68.	0.6	0
826	Abstract 4867: Identification of an inv(16)-encodedCBFA2T3-GLIS2fusion protein in 34% of non-infant acute megkaryoblastic leukemias: A report from the Pediatric Cancer Genome Project. , 2012, , .		0
827	Genome-Wide Association Study Identifies Germline Polymorphisms Associated with Relapse of Childhood Acute Lymphoblastic Leukemia. Blood, 2012, 120, 878-878.	0.6	0
828	Deep Sequencing Approach for Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia. Blood, 2012, 120, 1388-1388.	0.6	0

#	Article	IF	Citations
829	Second Neoplasms After Treatment of Childhood Acute Lymphoblastic Leukemia. Blood, 2012, 120, 661-661.	0.6	0
830	Global fitness in adult survivors of childhood acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology, 2013, 31, 10022-10022.	0.8	0
831	Prognostic Factors For Children With Acute Myeloid Leukemia Who Achieve Minimal Residual Disease-Negative Status After Induction Therapy. Blood, 2013, 122, 490-490.	0.6	0
832	Targeted Drug Therapy in Childhood Acute Lymphoblastic Leukemia. Hamatologie Und Bluttransfusion, 1996, , 62-66.	0.0	0
833	Alkylating agent exposure and sperm concentration in adult survivors of childhood cancer: A report from the St. Jude Lifetime (SJLIFE) Cohort Study.. Journal of Clinical Oncology, 2014, 32, 10010-10010.	0.8	0
834	Abstract 3083: The genetic landscape of Ph-like acute lymphoblastic leukemia. , 2014, , .		0
835	Abstract CT409: Dexamethasone (dex) and asparaginase increase triglycerides during acute lymphoblastic leukemia (ALL) therapy in children. , 2014, , .		0
836	A Murine Model of Asparaginase Allergy. Blood, 2014, 124, 2295-2295.	0.6	0
837	Tolerability of 6-Mercaptopurine (6MP) in Patients with Thiopurine Methyltransferase (TPMT) Heterozygosity in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 3722-3722.	0.6	0
838	Cryptic Truncating Rearrangements of the Erythropoietin Receptor in Ph-like Acute Lymphoblastic Leukemia. Blood, 2014, 124, 128-128.	0.6	0
839	Late Outcomes of Adult Survivors of Childhood Acute Lymphoblastic Leukemia (ALL) Diagnosed Between 1963-2002: A Report from the St. Jude Lifetime (SJLIFE) Cohort Study. Blood, 2014, 124, 853-853.	0.6	0
840	Acute Lymphoblastic Leukemia. , 2015, , 1-4.		0
841	Chemotherapy and brain function in long-term survivors of childhood acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology, 2015, 33, 10001-10001.	0.8	0
842	Body Mass Index Is Not Associated with Early Treatment Response or Clinical Outcome in Children with Acute Lymphoblastic Leukemia. Blood, 2015, 126, 1299-1299.	0.6	0
843	Evolution of neurocognitive function in long-term survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only.. Journal of Clinical Oncology, 2016, 34, 10505-10505.	0.8	0
844	Asparaginase May Affect Mercaptopurine Tolerability in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia. Blood, 2016, 128, 179-179.	0.6	0
845	Whole Transcriptome Sequencing Identified a Distinct Subtype of Acute Lymphoblastic Leukemia with Abnormalities of CREBBP and EP300. Blood, 2016, 128, 3912-3912.	0.6	0
846	Biomarkers of brain injury and neurologic outcomes in children treated with chemotherapy for acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology, 2017, 35, 10521-10521.	0.8	0

#	Article	IF	Citations
847	Hepatic injury after treatment for childhood cancer: A report from the St. Jude Lifetime Cohort study.. Journal of Clinical Oncology, 2017, 35, 10567-10567.	0.8	0
848	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. SSRN Electronic Journal, 0, , .	0.4	0
849	Traumatic and Bloody Lumbar Puncture at Diagnosis in Children with Acute Lymphoblastic Leukemia: A St. Jude Total XV and Total XVI Cohort Study. Blood, 2018, 132, 1380-1380.	0.6	0
850	The Effect of Asparaginase on Serum Triglycerides during Therapy for Acute Lymphoblastic Leukemia. Blood, 2018, 132, 2665-2665.	0.6	0
851	Mutational Landscape and Temporal Evolution during Treatment of Relapsed Acute Lymphoblastic Leukemia. Blood, 2018, 132, 917-917.	0.6	0
852	OR18-1 Leydig Cell Function in Adult Survivors of Childhood Cancer. Journal of the Endocrine Society, 2019, 3, .	0.1	0
853	Chronic health conditions (CHC) and late mortality in survivors of acute lymphoblastic leukemia (ALL) in the Childhood Cancer Survivor Study.. Journal of Clinical Oncology, 2019, 37, 10016-10016.	0.8	0
854	Effect of Dasatinib Vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized, Open-Label, Multicenter Study of the Chinese Children's Cancer Group. Blood, 2019, 134, 828-828.	0.6	0
855	Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid Leukemia. Blood, 2019, 134, 178-178.	0.6	0
856	Lack of Benefit of Extended Vincristine and Dexamethasone Pulses during Maintenance Treatment of Childhood Acute Lymphoblastic Leukemia: A Multicenter Randomized Controlled Study of Chinese Children Cancer Group (CCCG)-ALL-2015. Blood, 2019, 134, 2576-2576.	0.6	0
857	Longitudinal evaluation of alanine aminotransferase after treatment for childhood cancer. A report from the St. Jude Lifetime Cohort Study.. Journal of Clinical Oncology, 2020, 38, e22525-e22525.	0.8	0
858	The Impact of Genetic Ancestry on the Biology and Prognosis of Childhood Acute Lymphoblastic Leukemia. Blood, 2021, 138, 3476-3476.	0.6	0
859	Clinical Features and Cytoreduction Therapy in Children with Newly Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis. Blood, 2021, 138, 2295-2295.	0.6	0
860	The Impact of T Cell Immunity on Chemotherapy Response in Childhood Acute Lymphoblastic Leukemia. Blood, 2021, 138, 703-703.	0.6	0
861	Assays and molecular determinants of cellular drug resistance. , 2006, , 414-438.		0
862	Acute leukemia in countries with limited resources. , 2006, , 625-638.		0
863	Antibody-targeted therapy. , 0, , 639-647.		0
864	Late complications after leukemia therapy. , 2006, , 750-773.		0

#	Article	IF	Citations
865	Infectious disease complications in leukemia. , 2006, , 805-828.		0
866	Nursing care. , 0, , 882-893.		0
867	Remembering Donald Pinkel, MD: Acute lymphoblastic leukaemia pioneer September 7, 1926 â€“March 9, 2022. Leukemia, 2022, 36, 1444-1445.	3.3	0
868	Donald P. Pinkel: In Memoriam (1926â€“2022). Blood Cancer Discovery, 0, , OF1-OF3.	2.6	0
869	Bone mineral density (BMD) deficits in adult survivors of childhood cancer: Attributable risks and long-term consequences.. Journal of Clinical Oncology, 2022, 40, e22021-e22021.	0.8	0